

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number
WO 2004/092161 A1

(51) International Patent Classification⁷: **C07D 403/12**,
C07K 5/10, A61K 31/40

(21) International Application Number:
PCT/US2004/011011

(22) International Filing Date: 9 April 2004 (09.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/412,600 11 April 2003 (11.04.2003) US
60/510,317 10 October 2003 (10.10.2003) US

(71) Applicant (for all designated States except US): **VERTEX PHARMACEUTICALS INCORPORATED** [US/US];
130 Waverly Street, Cambridge, MA 02139-4242 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COTTRELL, Kevin, M.** [US/US]; 54 Pearl Street #3, Cambridge, MA 02139-4242 (US). **MAXWELL, John** [US/US]; 260 Manet Avenue, Quincy, MA 02169 (US). **PERNI, Robert, B.** [US/US]; 130 Robert Road, Marlborough, MA 01752 (US). **PITLIK, Janos** [HU/US]; 1 Robin Circle, Westborough, MA 01851 (US).

(74) Agent: **BADIA, Michael, C.**; Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139-4242 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE



INHIBITORS OF SERINE PROTEASES,
PARTICULARLY HCV NS3-NS4A PROTEASE

5

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of United States Provisional Application number 60/510,317, filed October 10, 2003, entitled "Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease", the entire contents of which is hereby incorporated by reference. This application also claims the benefit of United States Patent Application number 10/412,600, filed April 11, 2003, entitled "Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease", the entire contents of which is hereby incorporated by reference.

20

TECHNICAL FIELD OF THE INVENTION

[0002] The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to pharmaceutical compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to processes for preparing the compounds and methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.

25

30

BACKGROUND OF THE INVENTION

[0003] Infection by hepatitis C virus ("HCV") is a compelling human medical problem. HCV is recognized as

the causative agent for most cases of non-A, non-B hepatitis, with an estimated human sero-prevalence of 3% globally [A. Alberti et al., "Natural History of Hepatitis C," J. Hepatology, 31., (Suppl. 1), pp. 17-24 (1999)]. Nearly four million individuals may be infected in the United States alone [M.J. Alter et al., "The Epidemiology of Viral Hepatitis in the United States, Gastroenterol. Clin. North Am., 23, pp. 437-455 (1994); M. J. Alter "Hepatitis C Virus Infection in the United States," J. Hepatology, 31., (Suppl. 1), pp. 88-91 (1999)].

[0004] Upon first exposure to HCV only about 20% of infected individuals develop acute clinical hepatitis while others appear to resolve the infection spontaneously. In almost 70% of instances, however, the virus establishes a chronic infection that persists for decades [S. Iwarson, "The Natural Course of Chronic Hepatitis," FEMS Microbiology Reviews, 14, pp. 201-204 (1994); D. Lavanchy, "Global Surveillance and Control of Hepatitis C," J. Viral Hepatitis, 6, pp. 35-47 (1999)]. This usually results in recurrent and progressively worsening liver inflammation, which often leads to more severe disease states such as cirrhosis and hepatocellular carcinoma [M.C. Kew, "Hepatitis C and Hepatocellular Carcinoma", FEMS Microbiology Reviews, 14, pp. 211-220 (1994); I. Saito et. al., "Hepatitis C Virus Infection is Associated with the Development of Hepatocellular Carcinoma," Proc. Natl. Acad. Sci. USA, 87, pp. 6547-6549 (1990)]. Unfortunately, there are no broadly effective treatments for the debilitating progression of chronic HCV.

[0005] The HCV genome encodes a polyprotein of 3010-3033 amino acids [Q.L. Choo, et. al., "Genetic Organization and Diversity of the Hepatitis C Virus."

Proc. Natl. Acad. Sci. USA, 88, pp. 2451-2455 (1991); N. Kato et al., "Molecular Cloning of the Human Hepatitis C Virus Genome From Japanese Patients with Non-A, Non-B Hepatitis," Proc. Natl. Acad. Sci. USA, 87, pp. 9524-9528 (1990); A. Takamizawa et. al., "Structure and Organization of the Hepatitis C Virus Genome Isolated From Human Carriers," J. Virol., 65, pp. 1105-1113 (1991)]. The HCV nonstructural (NS) proteins are presumed to provide the essential catalytic machinery for viral replication. The NS proteins are derived by proteolytic cleavage of the polyprotein [R. Bartenschlager et. al., "Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions," J. Virol., 67, pp. 3835-3844 (1993); A. Grakoui et. al., "Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase-Dependent Polyprotein Cleavage Sites," J. Virol., 67, pp. 2832-2843 (1993); A. Grakoui et. al., "Expression and Identification of Hepatitis C Virus Polyprotein Cleavage Products," J. Virol., 67, pp. 1385-1395 (1993); L. Tomei et. al., "NS3 is a serine protease required for processing of hepatitis C virus polyprotein", J. Virol., 67, pp. 4017-4026 (1993)].

25 **[0006]** The HCV NS protein 3 (NS3) contains a serine protease activity that helps process the majority of the viral enzymes, and is thus considered essential for viral replication and infectivity. It is known that mutations in the yellow fever virus NS3 protease decrease viral infectivity [Chambers, T.J. et. al., "Evidence that the N-terminal Domain of Nonstructural Protein NS3 From Yellow Fever Virus is a Serine Protease Responsible for Site-Specific Cleavages in the Viral Polyprotein", Proc. Natl. Acad. Sci. USA, 87, pp. 8898-8902 (1990)]. The

first 181 amino acids of NS3 (residues 1027-1207 of the viral polyprotein) have been shown to contain the serine protease domain of NS3 that processes all four downstream sites of the HCV polyprotein [C. Lin et al., "Hepatitis C Virus NS3 Serine Proteinase: *Trans*-Cleavage Requirements and Processing Kinetics", J. Virol., 68, pp. 8147-8157 (1994)].

[0007] The HCV NS3 serine protease and its associated cofactor, NS4A, helps process all of the viral enzymes, and is thus considered essential for viral replication. This processing appears to be analogous to that carried out by the human immunodeficiency virus aspartyl protease, which is also involved in viral enzyme processing. HIV protease inhibitors, which inhibit viral protein processing, are potent antiviral agents in man, indicating that interrupting this stage of the viral life cycle results in therapeutically active agents. Consequently HCV NS3 serine protease is also an attractive target for drug discovery.

[0008] Several potential HCV protease inhibitors have been described [PCT publication Nos. WO 02/18369, WO 02/08244, WO 00/09558, WO 00/09543, WO 99/64442, WO 99/07733, WO 99/07734, WO 99/50230, WO 98/46630, WO 98/17679 and WO 97/43310, United States Patent 5,990,276, M. Llinas-Brunet et al., Bioorg. Med. Chem. Lett., 8, pp. 1713-18 (1998); W. Han et al., Bioorg. Med. Chem. Lett., 10, 711-13 (2000); R. Dunsdon et al., Bioorg. Med. Chem. Lett., 10, pp. 1571-79 (2000); M. Llinas-Brunet et al., Bioorg. Med. Chem. Lett., 10, pp. 2267-70 (2000); and S. LaPlante et al., Bioorg. Med. Chem. Lett., 10, pp. 2271-74 (2000)].

[0009] Furthermore, the current understanding of HCV has not led to any other satisfactory anti-HCV agents or treatments. Until recently, the only established therapy


for HCV disease was interferon treatment. However, interferons have significant side effects [M. A. Wlaker et al., "Hepatitis C Virus: An Overview of Current Approaches and Progress," DDT, 4, pp. 518-29 (1999); D. Moradpour et al., "Current and Evolving Therapies for Hepatitis C," Eur. J. Gastroenterol. Hepatol., 11, pp. 1199-1202 (1999); H. L. A. Janssen et al. "Suicide Associated with Alfa-Interferon Therapy for Chronic Viral Hepatitis," J. Hepatol., 21, pp. 241-243 (1994); P.F. Renault et al., "Side Effects of Alpha Interferon," Seminars in Liver Disease, 9, pp. 273-277. (1989)] and induce long term remission in only a fraction (~ 25%) of cases [O. Weiland, "Interferon Therapy in Chronic Hepatitis C Virus Infection", FEMS Microbiol. Rev., 14, pp. 279-288 (1994)]. Recent introductions of the pegylated forms of interferon (PEG-Intron® and Pegasys®) and the combination therapy of ribavirin and pegylated interferon (Rebetrol®) have resulted in only modest improvements in remission rates and only partial reductions in side effects. Moreover, the prospects for effective anti-HCV vaccines remain uncertain.

[0010] Thus, there is a need for more effective anti-HCV therapies. Such inhibitors would have therapeutic potential as protease inhibitors, particularly as serine protease inhibitors, and more particularly as HCV NS3 protease inhibitors. Specifically, such compounds may be useful as antiviral agents, particularly as anti-HCV agents.

30

SUMMARY OF THE INVENTION

[0011] The present invention provides a compound of formula I:



I

or a pharmaceutically acceptable salt thereof,
wherein:

R_9 and $R_{9'}$ are each independently:

hydrogen-,

(C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-,

[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
aliphatic-,

(C6-C10)-aryl-,

(C6-C10)-aryl-(C1-C12)aliphatic-,

(C3-C10)-heterocyclyl-,

(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,

(C5-C10)-heteroaryl-, or

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to three aliphatic carbon atoms in each
of R_9 and $R_{9'}$ are optionally replaced by O, N, NH, S,
SO, or SO₂ in a chemically stable arrangement;

wherein each of R_9 and $R_{9'}$ is independently and
optionally substituted with up to 3 substituents
independently selected from J;

J is halogen, -OR', -NO₂, -CN, -CF₃, -OCF₃, -R', oxo,
thioxo, =N(R'), =N(OR'), 1,2-methylenedioxy, 1,2-
ethylenedioxy, -N(R')₂, -SR', -SOR', -SO₂R', -SO₂N(R')₂,
-SO₃R', -C(O)R', -C(O)C(O)R', -C(O)C(O)OR',
-C(O)C(O)N(R')₂, -C(O)CH₂C(O)R', -C(S)R', -C(S)OR',
-C(O)OR', -OC(O)R', -C(O)N(R')₂, -OC(O)N(R')₂,
-C(S)N(R')₂, -(CH₂)₀₋₂NHC(O)R', -N(R')N(R')COR',

-N(R')N(R')C(O)OR', -N(R')N(R')CON(R')₂, -N(R')SO₂R',
 -N(R')SO₂N(R')₂, -N(R')C(O)OR', -N(R')C(O)R',
 -N(R')C(S)R', -N(R')C(O)N(R')₂, -N(R')C(S)N(R')₂,
 -N(COR')COR', -N(OR')R', -C(=NH)N(R')₂, -C(O)N(OR')R',
 -C(=NOR')R', -OP(O)(OR')₂, -P(O)(R')₂, -P(O)(OR')₂, or
 -P(O)(H)(OR'); wherein;

each R' is independently selected from:

hydrogen-,
 (C1-C12)-aliphatic-,
 (C3-C10)-cycloalkyl- or -cycloalkenyl-,
 [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
 aliphatic-,
 (C6-C10)-aryl-,
 (C6-C10)-aryl-(C1-C12)aliphatic-,
 (C3-C10)-heterocyclyl-,
 (C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
 (C5-C10)-heteroaryl-, and
 (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 5 atoms in R' are optionally and
 independently substituted with J;

wherein two R' groups bound to the same atom
 optionally form a 5- to 6-membered aromatic or a 3-
 to 7-membered saturated or partially unsaturated
 ring system having up to 3 heteroatoms independently
 selected from N, NH, O, S, SO, and SO₂, wherein said
 ring is optionally fused to a (C6-C10)aryl,
 (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a
 (C3-C10)heterocyclyl, wherein any ring has up to 3
 substituents selected independently from J;

R₁₀, R_{10'}, R₁₁, and R_{11'} are each independently:

hydrogen-,
 (C1-C12)-aliphatic-,
 (C3-C10)-cycloalkyl- or -cycloalkenyl-,

[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein any ring is optionally fused to a
(C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl,
or (C3-C10)heterocyclyl;

wherein up to 3 aliphatic carbon atoms in each of
R₁₀, R_{10'}, R₁₁, and R_{11'} are optionally replaced by a
heteroatom selected from O, NH, S, SO, or SO₂ in a
chemically stable arrangement;

wherein each of R₁₀, R_{10'}, R₁₁, and R_{11'} is
independently and optionally substituted with up to 3
substituents independently selected from J; or

R₁₀ is -OR' and R_{10'} is H; or

R₁₀ and R_{10'} are both -OR' or -SR'; or

R₁₀ and R_{10'} are both fluorine; or

R₁₀ and R_{10'} are optionally taken together with the carbon
atom to which they are bound to form a 5- to 7-membered
saturated or partially unsaturated ring system;

wherein the R₁₀ and R_{10'} atoms bound to the carbon
atom are independently C(H), N, NH, O, S, SO, or SO₂;

wherein said ring optionally contains up to 4
heteroatoms independently selected from N, NH, O, S,
SO, and SO₂;

wherein any atom is optionally singly or multiply
substituted with up to 2 substituents selected
independently from J; and

wherein said ring is optionally fused to a second
ring selected from (C6-C10)aryl, (C5-C10)heteroaryl,

(C3-C10)cycloalkyl, and a (C3-C10)heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; or

R₉ and R₁₀ are optionally taken together with the ring atoms to which they are bound to form a 5- to 6-membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system up to 3 heteroatoms independently selected from N, NH, O, S, SO, or SO₂; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; or

R₁₀ and R₁₁ are optionally taken together with the ring atoms to which they are bound to form a 5- to 6-membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3 heteroatoms independently selected from N, NH, O, S, SO, or SO₂; wherein said ring is optionally substituted with up to 3 substituents selected independently from J; or

R₉ and R₁₁ are optionally taken together with the ring atoms to which they are bound to form a bridged bicyclic saturated or partially unsaturated carbocyclic or heterocyclic ring system containing up to 10 atoms; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; wherein each heteroatom in the heterocyclic ring system is selected from the group consisting of N, NH, O, S, SO, or SO₂;

R₁ and R₃ are each independently:

(C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-,

[(C3-C10)-cycloalkyl- or -cycloalkenyl]-(C1-C12)-aliphatic-,

(C6-C10)-aryl-(C1-C12)aliphatic-, or

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 3 aliphatic carbon atoms in each of R₁ and R₃ are optionally replaced by a heteroatom selected from O, N, NH, S, SO, or SO₂ in a chemically stable arrangement;

wherein each of R₁ and R₃ is independently and optionally substituted with up to 3 substituents independently selected from J;

R₂, R₄, and R₇ are each independently:

hydrogen-,

(C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl-(C1-C12)-aliphatic-, or

(C6-C10)-aryl-(C1-C12)-aliphatic-;








wherein up to two aliphatic carbon atoms in each of R₂, R₄, and R₇ are optionally replaced by a heteroatom selected from O, N, NH, S, SO, and SO₂ in a chemically stable arrangement;

wherein each of R₂, R₄, and R₇ is optionally substituted with up to 3 substituents independently selected from J;

R₅ and R_{5'} are each independently hydrogen or (C1-C12)-aliphatic, wherein any hydrogen is optionally replaced with halogen; wherein any terminal carbon atom of R₅ is optionally substituted with sulfhydryl or hydroxy; or R₅ is Ph or -CH₂Ph and R_{5'} is H, wherein said Ph or -CH₂Ph group is optionally substituted with up to 3 substituents independently selected from J; or

R₅ and R_{5'} together with the atom to which they are bound optionally form a 3- to 6-membered saturated or partially unsaturated ring having up to 2 heteroatoms selected from N, NH, O, SO, and SO₂; wherein said ring is optionally substituted with up to 2 substituents selected independently from J;

W is:



5

wherein m is 0 or 1;

wherein each R₆ is independently:

hydrogen-,
 (C1-C12)-aliphatic-,
 (C6-C10)-aryl-,
 (C6-C10)-aryl-(C1-C12)aliphatic-,
 (C3-C10)-cycloalkyl- or cycloalkenyl-,
 [(C3-C10)-cycloalkyl- or cycloalkenyl]-(C1-C12)-
 aliphatic-,
 (C3-C10)-heterocyclyl-,
 (C3-C10)-heterocyclyl-(C1-C12)-aliphatic-,
 (C5-C10)-heteroaryl-, or
 (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 3 aliphatic carbon atoms in each R₆ is optionally replaced by a heteroatom selected from O, NH, S, SO, or SO₂ in a chemically stable arrangement;

wherein R₆ is optionally substituted with up to 3 J substituents; or

two R₆ groups, together with the nitrogen atom to which they are bound, optionally form a 5- to 6-membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3 heteroatoms independently selected from N, NH, O, S, SO, and SO₂, wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J;

wherein each R₈ is independently -OR'; or the R₈ groups together with the boron atom, is a (C3-C10)-membered heterocyclic ring having in addition to the boron up to 3 additional heteroatoms selected from N, NR', O, SO, and SO₂;

V is -C(O)-, -C(S)-, -S(O)-, or -S(O)₂-;

A is hydrogen or -C(R₁₂)(R_{12'})-T-R₁₃;

T is oxygen or a bond;

R₁₂ and R_{12'} are each independently:

hydrogen-, or

(C1-C6)-aliphatic-;

wherein up to two aliphatic carbon atoms in each of R₁₂ and R_{12'} are optionally replaced by a heteroatom selected from O, N, NH, S, SO, and SO₂ in a chemically stable arrangement; or

R₁₂ is absent and R_{12'} is =O;

R₁₃ is -C(O)R', -P(O)(OR')₂, -SO₃R', -R', or R₁₉;

R₁₉ is:

hydrogen,

(C1-C12)-aliphatic-,

(C6-C10)-aryl-(C1-C12)aliphatic-, or

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein R₁₉ is optionally substituted with up to 3 J substituents;

wherein up to 3 aliphatic carbon atoms in each R₁₉ are optionally replaced by a heteroatom selected from O, NR₁₉, S, SO, or SO₂ in a chemically stable arrangement;

wherein up to 3 aliphatic carbon atoms in each R₁₉ are optionally replaced with -C(O)-;

wherein R₁₉ is optionally substituted with up to 3 J substituents;

wherein any NR₁₉, taken together with the nitrogen and a carbon adjacent to the nitrogen, optionally forms a 5- to 7-membered ring system, wherein said ring system optionally contains up to three additional heteroatoms selected from O, N, NH, S, SO, and SO₂ in a chemically stable arrangement;

R₁₄ and R₁₅ are independently halogen, -OR', -OC(O)N(R')₂, -NO₂, -CN, -CF₃, -OCF₃, -R', 1,2-methylenedioxy, 1,2-ethylenedioxy, -N(R')₂, -SR', -SOR', -SO₂R', -SO₂N(R')₂, -SO₃R', -C(O)R', -C(O)C(O)R', -C(O)CH₂C(O)R', -C(S)R',

$-C(O)OR'$, $-OC(O)R'$, $-C(O)N(R')_2$, $-OC(O)N(R')_2$,
 $-C(S)N(R')_2$, or $-(CH_2)_{0-2}NHC(O)R'$;

R_{16} is R' , $-C(O)R'$, $-P(O)(OR')_2$, or $-SO_3R'$;

U is O, N, or a bond;

R_{18} and R_{18}' are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system;

wherein the R_{18} and R_{18}' atoms bound to the carbon atom are independently O or N;

wherein said ring optionally contains up to 1 additional heteroatom selected from N, NH, O, S, SO, and SO_2 ;

wherein any substitutable atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J;

wherein said ring is optionally fused to a second ring selected from (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, and a (C3-C10)heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J;

provided that when R_{18} and R_{18}' are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system, then R_{16} is R' ; or

R_{18}' is $=O$, $=CH_2$, $=N(R')$, or $=N(OR')$ and R_{18} is absent, provided that when R_{18} is absent and R_{18}' is $=CH_2$, then U is oxygen; and


provided that when R_{18} is absent and R_{18}' is $=O$, $=N(R')$ or $=N(OR')$, then U is a bond and R_{16} is R' .

[0012] The invention also relates to processes for preparing the above compounds and to compositions that comprise the above compounds and the use thereof. Such compositions may be used to pre-treat invasive devices to

be inserted into a patient, to treat biological samples, such as blood, prior to administration to a patient, and for direct administration to a patient. In each case the composition will be used to inhibit HCV replication and
 5 to lessen the risk of or the severity of HCV infection.

DETAILED DESCRIPTION OF THE INVENTION

[0013] The present invention provides a compound of
 10 formula I:



I

or a pharmaceutically acceptable salt thereof,
 wherein:

R₉ and R₉' are each independently:

hydrogen-,

(C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-,

[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
 aliphatic-,

(C6-C10)-aryl-,

(C6-C10)-aryl-(C1-C12)aliphatic-,

(C3-C10)-heterocyclyl-,

(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,

(C5-C10)-heteroaryl-, or

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to three aliphatic carbon atoms in each of R_9 and R_9' are optionally replaced by O, N, NH, S, SO, or SO₂ in a chemically stable arrangement;

wherein each of R_9 and R_9' is independently and optionally substituted with up to 3 substituents independently selected from J;

J is halogen, -OR', -NO₂, -CN, -CF₃, -OCF₃, -R', oxo, thioxo, =N(R'), =N(OR'), 1,2-methylenedioxy, 1,2-ethylenedioxy, -N(R')₂, -SR', -SOR', -SO₂R', -SO₂N(R')₂, -SO₃R', -C(O)R', -C(O)C(O)R', -C(O)C(O)OR', -C(O)C(O)N(R')₂, -C(O)CH₂C(O)R', -C(S)R', -C(S)OR', -C(O)OR', -OC(O)R', -C(O)N(R')₂, -OC(O)N(R')₂, -C(S)N(R')₂, -(CH₂)₀₋₂NHC(O)R', -N(R')N(R')COR', -N(R')N(R')C(O)OR', -N(R')N(R')CON(R')₂, -N(R')SO₂R', -N(R')SO₂N(R')₂, -N(R')C(O)OR', -N(R')C(O)R', -N(R')C(S)R', -N(R')C(O)N(R')₂, -N(R')C(S)N(R')₂, -N(COR')COR', -N(OR')R', -C(=NH)N(R')₂, -C(O)N(OR')R', -C(=NOR')R', -OP(O)(OR')₂, -P(O)(R')₂, -P(O)(OR')₂, or -P(O)(H)(OR'); wherein;

each R' is independently selected from:

hydrogen-,
 (C1-C12)-aliphatic-,
 (C3-C10)-cycloalkyl- or -cycloalkenyl-,
 [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
 (C6-C10)-aryl-,
 (C6-C10)-aryl-(C1-C12)aliphatic-,
 (C3-C10)-heterocyclyl-,
 (C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
 (C5-C10)-heteroaryl-, and
 (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 5 atoms in R' are optionally and independently substituted with J;

wherein two R' groups bound to the same atom optionally form a 5- to 6-membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3 heteroatoms independently selected from N, NH, O, S, SO, and SO₂, wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J;

R₁₀, R_{10'}, R₁₁, and R_{11'} are each independently:

hydrogen-,
 (C1-C12)-aliphatic-,
 (C3-C10)-cycloalkyl- or -cycloalkenyl-,
 [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
 aliphatic-,
 (C6-C10)-aryl-,
 (C6-C10)-aryl-(C1-C12)aliphatic-,
 (C3-C10)-heterocyclyl-,
 (C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
 (C5-C10)-heteroaryl-, or
 (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein any ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;

wherein up to 3 aliphatic carbon atoms in each of R₁₀, R_{10'}, R₁₁, and R_{11'} are optionally replaced by a heteroatom selected from O, NH, S, SO, or SO₂ in a chemically stable arrangement;

wherein each of R₁₀, R_{10'}, R₁₁, and R_{11'} is independently and optionally substituted with up to 3 substituents independently selected from J; or

R₁₀ is -OR' and R_{10'} is H; or

R₁₀ and R_{10'} are both -OR' or -SR'; or

R₁₀ and R_{10'} are both fluorine; or

R₁₀ and R_{10'} are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system;

wherein the R₁₀ and R_{10'} atoms bound to the carbon atom are independently C(H), N, NH, O, S, SO, or SO₂;

wherein said ring optionally contains up to 4 heteroatoms independently selected from N, NH, O, S, SO, and SO₂;

wherein any atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; and

wherein said ring is optionally fused to a second ring selected from (C₆-C₁₀)aryl, (C₅-C₁₀)heteroaryl, (C₃-C₁₀)cycloalkyl, and a (C₃-C₁₀)heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; or

R₉ and R₁₀ are optionally taken together with the ring atoms to which they are bound to form a 5- to 6-membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system up to 3 heteroatoms independently selected from N, NH, O, S, SO, or SO₂; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; or

R₁₀ and R₁₁ are optionally taken together with the ring atoms to which they are bound to form a 5- to 6-membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3 heteroatoms independently selected from N, NH, O, S, SO, or SO₂; wherein said ring is optionally substituted with up to 3 substituents selected independently from J; or

R₉ and R₁₁ are optionally taken together with the ring atoms to which they are bound to form a bridged bicyclic saturated or partially unsaturated carbocyclic

or heterocyclic ring system containing up to 10 atoms;
wherein said ring system is optionally substituted with
up to 3 substituents selected independently from J;
wherein each heteroatom in the heterocyclic ring system
is selected from the group consisting of N, NH, O, S,
SO, or SO₂;

R₁ and R₃ are each independently:

(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl- or -cycloalkenyl]-(C1-C12)-
aliphatic-,
(C6-C10)-aryl-(C1-C12)aliphatic-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 3 aliphatic carbon atoms in each of R₁
and R₃ are optionally replaced by a heteroatom selected
from O, N, NH, S, SO, or SO₂ in a chemically stable
arrangement;

wherein each of R₁ and R₃ is independently and
optionally substituted with up to 3 substituents
independently selected from J;

R₂, R₄, and R₇ are each independently:

hydrogen-,
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl-(C1-C12)-aliphatic-, or
(C6-C10)-aryl-(C1-C12)-aliphatic-;


wherein up to two aliphatic carbon atoms in each of
R₂, R₄, and R₇ are optionally replaced by a heteroatom
selected from O, N, NH, S, SO, and SO₂ in a chemically
stable arrangement;




wherein each of R₂, R₄, and R₇ is optionally
substituted with up to 3 substituents independently
selected from J;

R₅ and R₆ are each independently hydrogen or (C1-C12)-
aliphatic, wherein any hydrogen is optionally replaced

with halogen; wherein any terminal carbon atom of R_5 is optionally substituted with sulfhydryl or hydroxy; or R_5 is Ph or $-\text{CH}_2\text{Ph}$ and R_5' is H, wherein said Ph or $-\text{CH}_2\text{Ph}$ group is optionally substituted with up to 3 substituents independently selected from J; or R_5 and R_5' together with the atom to which they are bound optionally form a 3- to 6-membered saturated or partially unsaturated ring having up to 2 heteroatoms selected from N, NH, O, SO, and SO_2 ; wherein said ring is optionally substituted with up to 2 substituents selected independently from J;

W is:





wherein m is 0 or 1;

wherein each R₆ is independently:

hydrogen-,

(C1-C12)-aliphatic-,

(C6-C10)-aryl-,

(C6-C10)-aryl-(C1-C12)aliphatic-,

(C3-C10)-cycloalkyl- or cycloalkenyl-,

[(C3-C10)-cycloalkyl- or cycloalkenyl]-(C1-C12)-aliphatic-,

(C3-C10)-heterocyclyl-,

(C3-C10)-heterocyclyl-(C1-C12)-aliphatic-,

(C5-C10)-heteroaryl-, or

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 3 aliphatic carbon atoms in each R₆ is optionally replaced by a heteroatom selected from O, NH, S, SO, or SO₂ in a chemically stable arrangement;

wherein R₆ is optionally substituted with up to 3 J substituents; or

two R₆ groups, together with the nitrogen atom to which they are bound, optionally form a 5- to 6-membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3

heteroatoms independently selected from N, NH, O, S, SO, and SO₂, wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J;

wherein each R₈ is independently -OR'; or the R₈ groups together with the boron atom, is a (C3-C10)-membered heterocyclic ring having in addition to the boron up to 3 additional heteroatoms selected from N, NR', O, SO, and SO₂;

V is -C(O)-, -C(S)-, -S(O)-, or -S(O)₂-;

A is hydrogen or -C(R₁₂)(R_{12'})-T-R₁₃;

T is oxygen or a bond;

R₁₂ and R_{12'} are each independently:

hydrogen-, or

(C1-C6)-aliphatic-;

wherein up to two aliphatic carbon atoms in each of R₁₂ and R_{12'} are optionally replaced by a heteroatom selected from O, N, NH, S, SO, and SO₂ in a chemically stable arrangement; or

R₁₂ is absent and R_{12'} is =O;

R₁₃ is -C(O)R', -P(O)(OR')₂, -SO₃R', -R', or -R₁₉;

R₁₉ is:

hydrogen,

(C1-C12)-aliphatic-,

(C6-C10)-aryl-(C1-C12)aliphatic-, or

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 3 aliphatic carbon atoms in each R₁₉ are optionally replaced by a heteroatom selected from O, NR₁₉, S, SO, or SO₂ in a chemically stable arrangement;

wherein up to 3 aliphatic carbon atoms in each R₁₉ are optionally replaced with -C(O)-;

wherein R_{19} is optionally substituted with up to 3 J substituents;

wherein any NR_{19} , taken together with the nitrogen and a carbon adjacent to the nitrogen, optionally forms a 5- to 7-membered ring system, wherein said ring system optionally contains up to three additional heteroatoms selected from O, N, NH, S, SO, and SO_2 in a chemically stable arrangement;

R_{14} and R_{15} are independently halogen, $-OR'$, $-OC(O)N(R')_2$, $-NO_2$, $-CN$, $-CF_3$, $-OCF_3$, $-R'$, 1,2-methylenedioxy, 1,2-ethylenedioxy, $-N(R')_2$, $-SR'$, $-SOR'$, $-SO_2R'$, $-SO_2N(R')_2$, $-SO_3R'$, $-C(O)R'$, $-C(O)C(O)R'$, $-C(O)CH_2C(O)R'$, $-C(S)R'$, $-C(O)OR'$, $-OC(O)R'$, $-C(O)N(R')_2$, $-OC(O)N(R')_2$, $-C(S)N(R')_2$, or $-(CH_2)_{0-2}NHC(O)R'$;

R_{16} is R' , $-C(O)R'$, $-P(O)(OR')_2$, or $-SO_3R'$;

U is O, N, or a bond; and

R_{18} and $R_{18'}$ are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system;

wherein the R_{18} and $R_{18'}$ atoms bound to the carbon atom are independently O or N;

wherein said ring optionally contains up to 1 additional heteroatom selected from N, NH, O, S, SO, and SO_2 ;

wherein any substitutable atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J;

wherein said ring is optionally fused to a second ring selected from (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, and a (C3-C10)heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J;

provided that when R_{18} and $R_{18'}$ are optionally taken together with the carbon atom to which they are bound

to form a 5- to 7-membered saturated or partially unsaturated ring system, then R_{16} is R' ; or $R_{18'}$ is $=O$, $=CH_2$, $=N(R')$, or $=N(OR')$ and R_{18} is absent, provided that when R_{18} is absent and $R_{18'}$ is $=CH_2$, then U is oxygen; and provided that when R_{18} is absent and $R_{18'}$ is $=O$, $=N(R')$ or $=N(OR')$, then U is a bond and R_{16} is R' .

Definitions

[0014] The term "aryl" as used herein means a monocyclic or bicyclic carbocyclic aromatic ring system.

5 Phenyl is an example of a monocyclic aromatic ring system. Bicyclic aromatic ring systems include systems wherein both rings are aromatic, e.g., naphthyl, and systems wherein only one of the two rings is aromatic, e.g., tetralin. It is understood that as used herein,
10 the term "(C6-C10)-aryl-" includes any one of a C6, C7, C8, C9, and C10 monocyclic or bicyclic carbocyclic aromatic ring.

[0015] The term "heterocyclyl" as used herein means a monocyclic or bicyclic non-aromatic ring system having 1
15 to 3 heteroatom or heteroatom groups in each ring selected from O, N, NH, S, SO, and SO₂ in a chemically stable arrangement. In a bicyclic non-aromatic ring system embodiment of "heterocyclyl" one or both rings may contain said heteroatom or heteroatom groups. It is
20 understood that as used herein, the term "(C5-C10)-heterocyclyl-" includes any one of a C5, C6, C7, C8, C9, and C10 monocyclic or bicyclic non-aromatic ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from O, N, NH, and S in a chemically stable
25 arrangement.

[0016] The term "heteroaryl" as used herein means a monocyclic or bicyclic aromatic ring system having 1 to 3

heteroatom or heteroatom groups in each ring selected from O, N, NH, and S in a chemically stable arrangement. In such a bicyclic aromatic ring system embodiment of "heteroaryl":

- 5 - one or both rings may be aromatic; and
 - one or both rings may contain said heteroatom or heteroatom groups. It is understood that as used herein, the term "(C5-C10)-heteroaryl-" includes any one of a C5, C6, C7, C8, C9, and C10 monocyclic or bicyclic aromatic
10 ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from O, N, NH, and S in a chemically stable arrangement.

[0017] The term "aliphatic" as used herein means a straight chained or branched alkyl, alkenyl or alkynyl.

- 15 It is understood that as used herein, the term "(C1-C12)-aliphatic-" includes any one of a C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, and C12 straight or branched alkyl chain of carbon atoms. It is also understood that alkenyl or alkynyl embodiments need at least two carbon
20 atoms in the aliphatic chain. The term "cycloalkyl or cycloalkenyl" refers to a monocyclic or fused or bridged bicyclic carbocyclic ring system that is not aromatic. Cycloalkenyl rings have one or more units of unsaturation. It is also understood that as used herein,
25 the term "(C3-C10)-cycloalkyl- or -cycloalkenyl-" includes any one of a C3, C4, C5, C6, C7, C8, C9, and C10 monocyclic or fused or bridged bicyclic carbocyclic ring. Preferred cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl,
30 cycloheptyl, cycloheptenyl, nornbornyl, adamantyl and decalin-yl.

[0018] The phrase "chemically stable arrangement" as used herein refers to a compound structure that renders the compound sufficiently stable to allow manufacture and


administration to a mammal by methods known in the art. Typically, such compounds are stable at a temperature of 40°C or less, in the absence of moisture or other chemically reactive condition, for at least a week.

5

Preferred Embodiments

[0019] According to an embodiment of compounds of formula I, V is -C(O)-.

10 **[0020]** According to another embodiment, the present invention provides a compound of formula IA:



IA

15 wherein:

$R_1, R_2, R_3, R_4, R_5, R_5', R_7, R_9, R_9', R_{10}, R_{10'}, R_{11}, R_{11'}, R_{14}, R_{15}, R_{16}, R_{18}, R_{18'}, A, U,$ and W are as defined in any of the embodiments herein.

20 **[0021]** According to another embodiment of compounds of formula I,

A is $-C(R_{12})(R_{12}')-T-R_{13}$;

R_{12} and R_{12}' are both hydrogen;

T is oxygen;

R_{13} is $-C(O)R', -P(O)(OR')_2, -SO_3R',$ or $-R'$;

R_{14} and R_{15} are both $-R'$;

R_{18}' is $=O$ and R_{18} is absent;

U is a bond; and

R_{16} is R' , wherein R' is selected from:

(C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-,
 [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
 aliphatic-;


wherein up to 5 atoms in R' are optionally and
 independently substituted with J.

[0022] According to another embodiment of compounds of
 formula I,

R₁₃ is -C(O)R', -P(O)(OR')₂, or -R';

R₁₄ and R₁₅ are both -R' and R' is (C1-C12)-aliphatic-; and
 R₁₆ is R', wherein R' is (C1-C12)-aliphatic-.

[0023] According to another embodiment, the present
 invention provides a compound of formula IB:



IB

wherein:

R', R₁, R₂, R₃, R₄, R₅, R_{5'}, R₇, R₉, R_{9'}, R₁₀, R_{10'}, R₁₁,
 5 R_{11'}, R₁₃, and W are as defined in any of the embodiments
 herein.

[0024] According to an embodiment of compounds of
 formula IB, R₁₆ is -R' wherein R' is preferably methyl; R₁₄
 and R₁₅ are both -R' and R' is preferably methyl; R₁₃ is
 10 -C(O)R' or -P(O)(OR')₂, wherein R' is as defined in any of
 the embodiments herein; and R₁, R₂, R₃, R₄, R₅, R_{5'}, R₇, R₉,
 R_{9'}, R₁₀, R_{10'}, R₁₁, R_{11'}, and W are as defined in any of the
 embodiments herein.

[0025] According to another embodiment of compounds of
 15 formula I,

A is -C(R₁₂)(R_{12'})-T-R₁₃;

R_{12} is hydrogen and $R_{12'}$ is (C1-C6)-aliphatic-;

wherein up to two aliphatic carbon atoms in $R_{12'}$ are optionally replaced by a heteroatom selected from O, N, NH, S, SO, and SO₂ in a chemically stable arrangement;

T is oxygen;

R_{13} is $-C(O)R'$, $-P(O)(OR')_2$, $-SO_3R'$, or $-R'$;

R_{14} and R_{15} are both $-R'$;

$R_{18'}$ is =O and R_{18} is absent;

U is a bond; and

R_{16} is R' , wherein R' is selected from:

(C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-,

[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-;

wherein up to 5 atoms in R' are optionally and independently substituted with J.

[0026] According to another embodiment of compounds of formula I,


$R_{12'}$ is (C1-C6)-aliphatic-;

R_{13} is $-C(O)R'$, $-P(O)(OR')_2$, or $-R'$;

R_{14} and R_{15} are both $-R'$ and R' is (C1-C12)-aliphatic-;

R_{16} is R' , wherein R' is (C1-C12)-aliphatic-.

[0027] According to another embodiment, the present invention provides a compound of formula IC:



IC

5 wherein:

R', R₁, R₂, R₃, R₄, R₅, R_{5'}, R₇, R₉, R_{9'}, R₁₀, R_{10'}, R₁₁, R_{11'}, R_{12'}, R₁₃, and W are as defined in any of the embodiments herein.

[0028] According to an embodiment of compounds of formula IC, R₁₆ is -R' wherein R' is preferably methyl; R₁₄ and R₁₅ are both -R' and R' is preferably methyl; R₁₃ is -C(O)R' or -P(O)(OR')₂, wherein R' is as defined in any of the embodiments herein; R_{12'} is methyl and R₁, R₂, R₃, R₄, R₅, R_{5'}, R₇, R₉, R_{9'}, R₁₀, R_{10'}, R₁₁, R_{11'}, and W are as defined in any of the embodiments herein.

[0029] According to another embodiment of compounds of formula I,

A is -C(R₁₂)(R_{12'})-T-R₁₃;

R₁₂ is absent and R_{12'} is =O;

T is oxygen or a bond;

R₁₃ is -R₁₉;

R₁₄ and R₁₅ are both -R';

R_{18'} is =O and R₁₈ is absent;

U is a bond; and

R₁₆ is R', wherein R' is selected from:


(C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-,

[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-;

wherein up to 5 atoms in R' are optionally and independently substituted with J.

[0030] According to another embodiment, the present invention provides a compound of formula ID:



ID

wherein:

5 R' , R_1 , R_2 , R_3 , R_4 , R_5 , R_5' , R_7 , R_9 , R_9' , R_{10} , R_{10}' , R_{11} , R_{11}' , R_{12}' , R_{19} , T , and W are as defined in any of the embodiments herein.

10 **[0031]** According to an embodiment of compounds of formula ID, R_1 , R_2 , R_3 , R_4 , R_5 , R_5' , R_7 , R_9 , R_9' , R_{10} , R_{10}' , R_{11} , R_{11}' , and W are as defined in any of the embodiments herein;

T is a bond;

R_{16} is $-R'$ wherein R' is preferably methyl;

R_{14} and R_{15} are both $-R'$ and R' is preferably methyl;

15 R_{13} is R_{19} , wherein R_{19} is as defined in any of the embodiments herein.

[0032] According to another embodiment of compounds of formula ID, R_{19} is:

(C1-C12)-aliphatic-,

wherein 1 to 2 aliphatic carbon atoms in each R_{19} are optionally replaced by a heteroatom selected from O or NR_{19} , in a chemically stable arrangement;

wherein 1 to 2 aliphatic carbon atoms in each R_{19} is optionally replaced with $-C(O)-$;

wherein R_{19} is optionally substituted with up to 3 J substituents.

[0033] According to a preferred embodiment of compounds of formula ID, R_{19} is:

(C3-C6)-aliphatic-,

wherein 1 to 2 aliphatic carbon atoms in each R_{19} are optionally replaced by a heteroatom selected from O or NR_{19} , in a chemically stable arrangement;

wherein 1 to 2 aliphatic carbon atoms in each R_{19} is optionally replaced with $-C(O)-$;

wherein R_{19} is optionally substituted with up to 3 J substituents.

[0034] According to another embodiment of compounds of formula I,

R_{18} is $=CH_2$, and R_{18} is absent;

U is oxygen;

R_{16} is R' , $-C(O)R'$, $-P(O)(OR')_2$, or $-SO_3R'$;

R_{14} and R_{15} are both $-R'$; and


A is hydrogen.

[0035] According to another embodiment of compounds of formula I,

R_{16} is R' , $-C(O)R'$, or $-P(O)(OR')_2$;

R_{14} and R_{15} are both $-R'$ and R' is (C1-C12)-aliphatic-.

[0036] According to another embodiment, the present invention provides a compound of formula IE:



5

IE

wherein:

R' , R_1 , R_2 , R_3 , R_4 , R_5 , R_5' , R_7 , R_9 , R_9' , R_{10} , R_{10}' , R_{11} , R_{11}' , R_{16} , and W are as defined in any of the embodiments herein.

10

[0037] According to an embodiment of compounds of formula IE, R_{16} is $-C(O)R'$, $-P(O)(OR')_2$; R_{14} and R_{15} are both $-R'$ and R' is preferably methyl; A is hydrogen; and

R_1 , R_2 , R_3 , R_4 , R_5 , R_5' , R_7 , R_9 , R_9' , R_{10} , R_{10}' , R_{11} , R_{11}' , and W are as defined in any of the embodiments herein.


[0038] According to an embodiment of compounds of formula I,

- 5 R_{18}' is $=N(R')$ or $=N(OR')$ and R_{18} is absent;
 U is a bond;
 R_{16} is R' ;
 R_{14} and R_{15} are both $-R'$; and
 A is hydrogen.

[0039] In another embodiment of compounds of formula I, U is $-NR'-$.

[0040] According to another embodiment of compounds of formula I, R_{14} and R_{15} are both $-R'$ and R' is (C1-C12)-aliphatic-.

[0041] According to another embodiment, the present invention provides a compound of formula IF:



IF

wherein:

- 20 R' , R_1 , R_2 , R_3 , R_4 , R_5 , R_5' , R_7 , R_9 , R_9' , R_{10} , R_{10}' , R_{11} , R_{11}' , R_{16} , R_{18}' , and W are as defined in any of the embodiments herein.

- [0042]** According to an embodiment of compounds of formula IF, R_{18}' is $=N(R')$ or $=N(OR')$ and R_{18} is absent; R_{16} is R' ; R_{14} and R_{15} are both $-R'$ and R' is preferably
 25 methyl; A is hydrogen; and R_1 , R_2 , R_3 , R_4 , R_5 , R_5' , R_7 , R_9 , R_9' , R_{10} , R_{10}' , R_{11} , R_{11}' , and W are as defined in any of the embodiments herein.

[0043] According to another embodiment of compounds of formula I,

R₁₈ and R_{18'} are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system;

wherein the R₁₈ and R_{18'} atoms bound to the carbon atom are independently O or N;

wherein said ring optionally contains up to 1 additional heteroatom selected from N, NH, O, S, SO, and SO₂;

wherein any substitutable atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J;

wherein said ring is optionally fused to a second ring selected from (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, and a (C3-C10)heterocyclyl, wherein said second ring has up to 3 substituents selected

5 independently from J;

U is a bond;

R₁₆ is R';


R₁₄ and R₁₅ are both -R'; and

A is hydrogen.

[0044] According to another embodiment of compounds of formula I,

10 the R₁₈ and R_{18'} atoms bound to the carbon atom are O and the ring formed when R₁₈ and R_{18'} are optionally taken together with the carbon atom to which they are bound optionally contains up to 1 additional oxygen atom and is optionally substituted with up to 2 J substituents.

[0045] According to another embodiment, the present invention provides a compound of formula IG:



IG

wherein:


r is 0, 1, or 2, R_{16} is R' , R' , R_1 , R_2 , R_3 , R_4 , R_5 , R_5' ,
 5 R_7 , R_9 , R_9' , R_{10} , R_{10}' , R_{11} , R_{11}' , and W are as defined in any
 of the embodiments herein.

[0046] According to an embodiment of compounds of
 formula IG, the R_{18} and R_{18}' atoms bound to the carbon atom
 are O; the ring formed when R_{18} and R_{18}' are optionally
 10 taken together with the carbon atom to which they are
 bound is a 5- or 6-membered ring system optionally
 substituted with up to 2 J substituents; R_{16} is R' ; R_{14} and
 R_{15} are both $-R'$ and R' is preferably methyl; A is
 hydrogen; and R_1 , R_2 , R_3 , R_4 , R_5 , R_5' , R_7 , R_9 , R_9' , R_{10} , R_{10}' ,
 15 R_{11} , R_{11}' , and W are as defined in any of the embodiments
 herein.

[0047] According to another embodiment, this invention
 does not include compounds wherein T is 3-acetyl-4,5-
 dimethyl-1H-pyrrole (e.g., see compounds 63-64 at page
 95, and compounds 66-67 at page 96 of WO 03/087092).

[0048] According to another embodiment, this invention
 does not include compounds wherein:

V is $-C(O)-$, $-C(S)-$, $-S(O)-$, or $-S(O)_2-$; and
 radical T is:



wherein:

R_{20} is $-H$, $-S(O)R^o$, $-S(O)_2R^o$, $-C(O)R^o$, $-C(O)OR^o$, $-C(O)N(R^o)_2$, $-N(R^o)C(O)R^o$, $-N(COR^o)COR^o$, $-SO_2N(R^o)_2$, $-SO_3R^o$, $-C(O)C(O)R^o$, $-C(O)CH_2C(O)R^o$, $-C(S)R^o$, $-C(S)N(R^o)_2$, $-(CH_2)_{0-2}NHC(O)R^o$, $-N(R^o)N(R^o)COR^o$, $-N(R^o)N(R^o)C(O)OR^o$, $-N(R^o)N(R^o)CON(R^o)_2$, $-N(R^o)SO_2R^o$, $-N(R^o)SO_2N(R^o)_2$, $-N(R^o)C(O)OR^o$, $-N(R^o)C(O)R^o$, $-N(R^o)C(S)R^o$, $-N(R^o)C(O)N(R^o)_2$, $-N(R^o)C(S)N(R^o)_2$, $-N(COR^o)COR^o$, $-N(OR^o)R^o$, $-C(=NH)N(R^o)_2$, $-C(O)N(OR^o)R^o$, $-C(=NOR^o)R^o$, $-OP(O)(OR^o)_2$, $-P(O)(R^o)_2$, $-P(O)(OR^o)_2$, or $-P(O)(H)(OR^o)$;

R_{21} and R_{22} are independently halogen, $-OR^o$, $-OC(O)N(R^o)_2$, $-NO_2$, $-CN$, $-CF_3$, $-OCF_3$, $-R^o$, oxo, 1,2-methylenedioxy, 1,2-ethylenedioxy, $-N(R^o)_2$, $-SR^o$, $-SOR^o$, $-SO_2R^o$, $-SO_2N(R^o)_2$, $-SO_3R^o$, $-C(O)R^o$, $-C(O)C(O)R^o$, $-C(O)CH_2C(O)R^o$, $-C(S)R^o$, $-C(O)OR^o$, $-OC(O)R^o$, $-C(O)N(R^o)_2$, $-OC(O)N(R^o)_2$, $-C(S)N(R^o)_2$, $-(CH_2)_{0-2}NHC(O)R^o$;

Z_2 is $=O$, $=NR^o$, $=NOR^o$, or $=CH_2$;

R_{23} is $-OR^o$, $-CF_3$, $-OCF_3$, $-R^o$, $-N(R^o)_2$, $-C(O)R^o$, or $-N(R^o)COR^o$;

two R^o groups together with the atoms to which they
 5 are bound form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, or SO_2 , wherein the ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, and

wherein any ring has up to 3 substituents selected independently from J₃; or

each R^o is independently selected from:

hydrogen-,

5 (C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl or -cycloalkenyl-,

[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,

(C6-C10)-aryl-,

10 (C6-C10)-aryl-(C1-C12)aliphatic-,

(C3-C10)-heterocyclyl-,

(C6-C10)-heterocyclyl-(C1-C12)aliphatic-,

(C5-C10)-heteroaryl-, or

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-,

15 wherein R^o has up to 3 substituents selected independently from J₃; and

J₃ is halogen, -OR^o, -OC(O)N(R^o)₂, -NO₂, -CN, -CF₃,

-OCF₃, -R^o, oxo, thioxo, 1,2-methylenedioxy, -N(R^o)₂, -SR^o,

-SOR^o, -SO₂R^o, -SO₂N(R^o)₂, -SO₃R^o, -C(O)R^o, -C(O)C(O)R^o,

20 -C(O)CH₂C(O)R^o, -C(S)R^o, -C(O)OR^o, -OC(O)R^o, -C(O)N(R^o)₂,

-OC(O)N(R^o)₂, -C(S)N(R^o)₂, -(CH₂)₀₋₂NHC(O)R^o,

-N(R^o)N(R^o)COR^o, -N(R^o)N(R^o)C(O)OR^o, -N(R^o)N(R^o)CON(R^o)₂,

-N(R^o)SO₂R^o, -N(R^o)SO₂N(R^o)₂, -N(R^o)C(O)OR^o, -N(R^o)C(O)R^o,

-N(R^o)C(S)R^o, -N(R^o)C(O)N(R^o)₂, -N(R^o)C(S)N(R^o)₂,

25 -N(COR^o)COR^o, -N(OR^o)R^o, -CN, -C(=NH)N(R^o)₂, -C(O)N(OR^o)R^o,

-C(=NOR^o)R^o, -OP(O)(OR^o)₂, -P(O)(R^o)₂, -P(O)(OR^o)₂, or

-P(O)(H)(OR^o) (e.g., see compounds of formula II at page 22 of WO 03/087092).

[0049] According to another embodiment of compounds of formula I, when R₁₈' is =O, R₁₈ is absent, U is a bond, and R₁₆ is R', then A is -C(R₁₂)(R₁₂')-T-R₁₃.

[0050] According to another embodiment of compounds of formula I, when A is hydrogen, R₁₆ is R', -C(O)R', -P(O)(OR')₂, or -SO₃R';

U is O, or N, or a bond; and

R_{18} and R_{18}' are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system;

wherein the R_{18} and R_{18}' atoms bound to the carbon atom are independently O or N;

wherein said ring optionally contains up to 1 additional heteroatom selected from N, NH, O, S, SO, and SO₂;

wherein any substitutable atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J;


wherein said ring is optionally fused to a second ring selected from (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, and a (C3-C10)heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J;

provided that when R_{18} and R_{18}' are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system, then R_{16} is R'; or


R_{18}' is =O, =CH₂, =N(R'), or =N(OR') and R_{18} is absent, provided that when R_{18} is absent and R_{18}' is =CH₂, then U is oxygen; and

provided that when R_{18} is absent and R_{18}' is =O, =N(R') or =N(OR'), then U is a bond and R_{16} is R'.

[0051] According to another embodiment of compounds of formula I, the



radical is:



wherein:


n is 0, 1, or 2;

Z and Z' are independently C(H), N, NH, O, or S;


5 R₉, R_{9'}, R₁₁, and R_{11'} are as defined in any of the embodiments herein; and

the spirocyclic ring containing Z and Z' is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.

10 **[0052]** According to another embodiment the



radical is:



wherein:


R₁₁ and R_{11'} are both H;

15 n is 0, 1, or 2;


R₉ and R_{9'} are as defined in any of the embodiments herein; and

the spirocyclic ring containing Z and Z' is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.

20 **[0053]** According to a preferred embodiment, the




radical is:



wherein:

n is 0 or 1.

- 5 **[0054]** According to another embodiment, the present invention provides a compound of formula IH:




IH


wherein:

- 10 $R_1, R_2, R_3, R_4, R_5, R_5', R_7, R_9, R_9', R_{11}, R_{11'}, R_{14}, R_{15}, R_{16}, R_{18}, R_{18'}, n, V, A, U, Z, Z'$ and W are as defined in any of the embodiments herein.

[0055] According to another embodiment the



radical is:



15


wherein:

Z and Z' are independently $C(H), N, NH, O,$ or S ;

R_9 , $R_{9'}$, R_{11} , and $R_{11'}$ are as defined in any of the embodiments herein; and

the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.

[0056] According to another embodiment, the present invention provides a compound of formula IJ:



IJ


wherein:

R_1 , R_2 , R_3 , R_4 , R_5 , $R_{5'}$, R_7 , R_9 , $R_{9'}$, R_{11} , $R_{11'}$, R_{14} , R_{15} , R_{16} , R_{18} , $R_{18'}$, V, A, U, Z, Z' and W are as defined in any of the embodiments herein; and


the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.

[0057] According to a preferred embodiment for compounds of formula IJ, Z and Z' are S, R_9 and $R_{9'}$ are H, R_1 , R_2 , R_3 , R_4 , R_5 , $R_{5'}$, R_7 , R_{11} , $R_{11'}$, R_{14} , R_{15} , R_{16} , R_{18} , $R_{18'}$, V, A, U, and W are as defined in any of the embodiments herein and the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.

[0058] According to another embodiment of compounds of formula I, the




radical is:




wherein:

R_9 , $R_{9'}$, R_{11} , and $R_{11'}$ are H.

5 **[0059]** In a preferred embodiment, the




radical is:



wherein:

R_9 , $R_{9'}$, R_{11} , and $R_{11'}$ are H.

10 **[0060]** According to another embodiment, the present invention provides a compound of formula IK:




IK

wherein:

15 R_1 , R_2 , R_3 , R_4 , R_5 , R_5' , R_7 , R_9 , $R_{9'}$, R_{11} , $R_{11'}$, R_{14} , R_{15} , R_{16} , R_{18} , $R_{18'}$, V , A , U , and W are as defined in any of the embodiments herein.

[0061] According to another embodiment of compounds of formula I, in the



R₉, R₁₀, R_{10'}, R₁₁, and R_{11'} are H; and

R_{9'} is:



(C1-C12)-aliphatic-,

5 (C3-C10)-cycloalkyl- or -cycloalkenyl-;


wherein up to three aliphatic carbon atoms in R₉ may be replaced by O, N, NH, S, SO, or SO₂;

wherein R_{9'} is independently and optionally substituted with up to 3 substituents independently selected from J.

10 **[0062]** According to another embodiment of compounds of formula I, the



15 **[0063]** According to another embodiment of compounds of formula I, in the



R₉, R_{9'}, R₁₀, R₁₁, and R_{11'} are H; and

R_{10'} is:

20 (C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-,


(C6-C10)-aryl-,

wherein any ring is optionally fused to a
(C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl,
or (C3-C10)heterocyclyl;


wherein up to 3 aliphatic carbon atoms in R₁₀' may be
5 replaced by a heteroatom selected from O, NH, S, SO, or
SO₂ in a chemically stable arrangement;

wherein R₁₀', is independently and optionally
substituted with up to 3 substituents independently
selected from J.


10 **[0064]** According to another embodiment of compounds of
formula I, the



radical is:



[0065] According to yet another embodiment of
15 compounds of formula I, in the



radical

R₉, R₉', R₁₀, R₁₀', and R₁₁ are H; and

R₁₁' is:

(C1-C12)-aliphatic-,

20 (C3-C10)-cycloalkyl- or -cycloalkenyl-,



(C6-C10)-aryl-,

wherein any ring is optionally fused to a
(C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl,
or (C3-C10)heterocyclyl;


wherein up to 3 aliphatic carbon atoms in R_{11}' , may be replaced by a heteroatom selected from O, NH, S, SO, or SO_2 in a chemically stable arrangement;

wherein R_{11}' , is independently and optionally
 5 substituted with up to 3 substituents independently selected from J.

[0066] According to another embodiment of compounds of formula I, the



[0067] According to another embodiment of compounds of formula I, in the



R_9 , R_{10} , R_{11} , and R_{11}' , are H; and

15 R_9 , and R_{10}' , are:


(C1-C12)-aliphatic-,


(C3-C10)-cycloalkyl- or -cycloalkenyl-,

wherein up to 3 aliphatic carbon atoms in R_9 , and R_{10}' , may be replaced by a heteroatom selected from O, NH, S, SO , or SO_2 in a chemically stable arrangement;


wherein R_9 , and R_{10}' , are independently and optionally substituted with up to 3 substituents independently selected from J.

[0068] According to another embodiment of compounds of formula I, the
 25





[0069] According to another embodiment of compounds of formula I, in the



5 R_9 , $R_{9'}$, $R_{10'}$, R_{11} , and $R_{11'}$ are H; and

R' is selected from:

(C6-C10)-aryl-,

(C6-C10)-aryl-(C1-C12)aliphatic-,

(C3-C10)-heterocyclyl-,



10 (C3-C10)-heterocyclyl-(C1-C12)aliphatic-,


(C5-C10)-heteroaryl-, and

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 5 atoms in R' are optionally and independently substituted with J.


15 **[0070]** According to another embodiment of compounds of formula I, the






5 wherein up to 5 atoms in R' are optionally and independently substituted with J.

[0071] According to another embodiment of compounds of formula I, the




radical is:



10

wherein up to 5 atoms in R' are optionally and independently substituted with J.

[0072] According to yet another embodiment of compounds of formula I, in the



R₉, R_{9'}, R_{10'}, R₁₁, and R_{11'} are H; and

R' is selected from:



(C6-C10)-aryl-(C1-C12)aliphatic-,

(C3-C10)-heterocyclyl-(C1-C12)aliphatic-, and

10 (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;


wherein up to 5 atoms in R' are optionally and independently substituted with J.

[0073] According to a preferred embodiment of compounds of formula I, the



wherein up to 5 atoms in R' are optionally and independently substituted with J.

[0074] According to another embodiment, the present
20 invention provides a compound of formula IL:




IL


wherein:

R', R₁, R₂, R₃, R₄, R₅, R_{5'}, R₇, R₉, R_{9'}, R₁₁, R_{11'}, R₁₄,
 R₁₅, R₁₆, R₁₈, R_{18'}, V, A, U, and W are as defined in any of
 5 the embodiments herein.

[0075] According to another embodiment of compounds of
 formula I, the



radical is:



10 wherein;


ring A is a 5- to 6-membered aromatic or a 3- to
 7-membered non-aromatic ring system having up to 3
 heteroatoms independently selected from N, NH, O, SO, or
 SO₂;

15 wherein said ring A is optionally fused to a (C6-
 C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-
 C10)heterocyclyl;


wherein any ring has up to 3 substituents selected
 independently from J; and

20 R₉, R_{9'}, R_{10'}, and R_{11'} are as defined in any of the
 embodiments herein.


[0076] According to another embodiment of compounds of
 formula I, the





radical is:





25





[0077] According to another embodiment of compounds of formula I, the




[0078] According to another embodiment of compounds of formula I, the



10 **[0079]** According to a preferred embodiment, the



[0080] According to another embodiment, the present invention provides a compound of formula IM:




IM


wherein:

5 R_1 , R_2 , R_3 , R_4 , R_5 , R_5' , R_7 , R_9 , R_9' , R_{10}' , R_{11}' , R_{14} , R_{15} , R_{16} , R_{18} , R_{18}' , V , A , U , W , and ring A are as defined in any of the embodiments herein.

[0081] According to another embodiment of compounds of formula I, the



radical is:



10

wherein;

ring A is a 5- to 6-membered aromatic or a 3- to 7-membered non-aromatic ring system having up to 3 heteroatoms independently selected from N , NH , O , SO , or SO_2 ;

15


wherein said ring A is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;

wherein any ring has up to 3 substituents selected independently from J ; and


20

R_9' , R_{10}' , R_{11} , and R_{11}' are as defined in any of the embodiments herein.


[0082] According to another embodiment of compounds of formula I, the




radical is:




10 **[0083]** According to yet another embodiment of compounds of formula I, the



radical is:



15 **[0084]** According to another embodiment, the present invention provides a compound of formula IN:




IN


wherein:

R₁, R₂, R₃, R₄, R₅, R_{5'}, R₇, R₉, R_{9'}, R₁₀, R₁₁, R_{11'}, R₁₄, R₁₅,
 5 R₁₆, R₁₈, R_{18'}, V, A, U, W, and ring A are as defined in any
 of the embodiments herein.

[0085] According to another embodiment of compounds of
 formula I, the



radical is:



10

wherein:

ring B forms a 3- to a 20-membered carbocyclic or
 heterocyclic ring system;

wherein each ring B is either aromatic or
 15 nonaromatic;



wherein each heteroatom in the heterocyclic ring
 system is N, NH, O, SO, or SO₂;

wherein ring B is optionally fused to a (C6-
 C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-
 20 C10)heterocyclyl;


wherein each ring has up to 3 substituents selected
 independently from J; and

R₉ and R₁₁ are as defined in any of the embodiments
 herein.

[0086] According to another embodiment, the



[0087] According to yet another embodiment, the
5 present invention provides a compound of formula IO:




IO

wherein:


10 R_1 , R_2 , R_3 , R_4 , R_5 , R_5' , R_7 , R_9' , R_{11}' , R_{14} , R_{15} , R_{16} , R_{18} , R_{18}' , V , A , U , W , and ring B are as defined in any of the embodiments herein.

[0088] According to another embodiment, W in compounds of formula I is:




wherein in the W , the NR_6R_6 is selected from $-NH-(C1-C6$ aliphatic), $-NH-(C3-C6$ cycloalkyl), $-NH-CH(CH_3)-aryl$, or $-NH-CH(CH_3)-heteroaryl$, wherein said aryl or said heteroaryl is optionally substituted with up to 3
20 halogens.


[0089] According to another embodiment in compounds of formula I, the NR_6R_6 in the W radical is:




[0090] According to another embodiment in compounds of formula I, the NR_6R_6 in the W radical is:




[0091] More preferably, in the W, the NR_6R_6 is:




[0092] Even more preferably, in the W, the NR_6R_6 is:



[0093] According to another embodiment in compounds of formula I, the NR_6R_6 in the W radical is:




[0094] According to another embodiment in compounds of formula I, the NR_6R_6 in the W radical is:



5


[0095] In yet another embodiment, in the W, the NR_6R_6



is:


[0096] According to another embodiment, the present invention provides a compound of formula IP:

10




IP

[0100] According to a preferred embodiment in compounds of formula I, R_5 is hydrogen and R_5 is:



[0101] According to another embodiment, the present invention provides a compound of formula IQ:




IQ


wherein:

R_1 , R_2 , R_3 , R_4 , R_6 , R_7 , R_9 , R_9' , R_{10} , R_{10}' , R_{11} , R_{11}' , R_{14} , R_{15} , R_{16} , R_{18} , R_{18}' , V , A , and U are as defined in any of the embodiments herein.

[0102] According to a preferred embodiment for compounds of formula IQ, R_1 , R_2 , R_3 , R_4 , R_7 , R_9 , R_9' , R_{10} , R_{10}' , R_{11} , R_{11}' , R_{14} , R_{15} , R_{16} , R_{18} , R_{18}' , V , A , and U are as defined in any of the embodiments herein, and NR_6R_6 is:



[0103] According to another embodiment in compounds of formula I, R_5 and R_5 is:




[0104] According to another embodiment for compounds of formula I, R_2 , R_4 , and R_7 , are each independently H, methyl, ethyl, or propyl.

[0105] According to a preferred embodiment R_2 , R_4 , and R_7 are each H.

[0106] According to another embodiment, the present invention provides a compound of formula IR:

5




IR


wherein:

R_1 , R_2 , R_3 , R_4 , R_6 , R_7 , R_9 , R_9' , R_{10} , R_{10}' , R_{11} , R_{11}' , R_{14} , R_{15} , R_{16} , R_{18} , R_{18}' , V , A , and U are as defined in any of the embodiments herein.


[0107] According to a preferred embodiment for compounds of formula IR, R_1 , R_2 , R_3 , R_4 , R_7 , R_9 , R_9' , R_{10} , R_{10}' , R_{11} , R_{11}' , R_{14} , R_{15} , R_{16} , R_{18} , R_{18}' , V , A , and U are as defined in any of the embodiments herein, and NR_6R_6 is:




[0108] According to another embodiment in compounds of formula I, R_3 is:




[0109] According to a preferred embodiment in compounds of formula I, R_3 is:



[0110] According to a more preferred embodiment in compounds of formula I, R_3 is:



5 **[0111]** According to another embodiment, the present invention provides a compound of formula IS:




IS


10 wherein:

R_1 , R_6 , R_9 , R_9' , R_{10} , R_{10}' , R_{11} , R_{11}' , R_{14} , R_{15} , R_{16} , R_{18} , R_{18}' , V , A , and U are as defined in any of the embodiments herein.

15 **[0112]** According to another embodiment in compounds of formula I, R_1 is:




[0113] According to a preferred embodiment in compounds of formula I, R_1 is:



[0114] More preferably, R_1 is cyclohexyl.

[0115] According to another embodiment, the present invention provides a compound of formula IT:

5




IT

wherein:

R_6 , R_9 , R_9' , R_{10} , R_{10}' , R_{11} , R_{11}' , R_{14} , R_{15} , R_{16} , R_{18} , R_{18}' ,
 10 V, A, and U are as defined in any of the embodiments
 herein.

[0116] According to another embodiment for compounds of formula IT, R_6 , R_9 , R_9' , R_{10} , R_{10}' , R_{11} , R_{11}' , and R_{12} are as defined in any of the embodiments herein, and NR_6R_6 is:



[0117] According to another embodiment for compounds of formulae I, and IA-IT, R_{14} and R_{15} are both $-R'$ and R' is $-(C1-C6 \text{ aliphatic})$. More preferably, R_{14} and R_{15} are both methyl.

20 **[0118]** The compounds of this invention may contain one or more asymmetric carbon atoms and thus may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly

included in the present invention. Each stereogenic carbon may be of the R or S configuration.

[0119] Preferably, the compounds of this invention have the structure and stereochemistry depicted in formulae IA-IT.

[0120] Any of the preferred embodiments recited herein, including those embodiments in the above species, may define formula I individually or be combined to produce a preferred embodiment of this invention.

[0121] The compounds of this invention contain, and may be modified to contain, appropriate functionalities to enhance selective biological properties compared to the corresponding parent compound. Such modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.

[0122] Without being bound by theory, we believe the compounds of this invention may enhance biological properties by behaving as prodrugs.

[0123] Chemical modifications of a drug into a bio- or chemically-reversible prodrug can confer temporary aqueous solubility to the drug substance that allows absorption following oral administration. See generally, Liu, S.; Han, C.; Wang, B. "Prodrug Derivatization as a Means to Enhance the Delivery of Peptide and Peptidomimetic Drugs" in *Frontiers of Biotechnology and Pharmaceuticals*, Ming Guo, ed, Science Press, New York, pp. 291-310 (2002) and Borchardt, R.T. and Wang, B. "Prodrug Strategies to Improve the Oral Absorption of Peptides and Peptide Mimetics" in *Controlled Drug Delivery. Designing Technologies for the Future*. Park. K.

and Mrsny, R.J. Eds, American Chemical Society,
Washington, D.C., pp. 36-45 (2000)

[0124] Prodrug strategies which rely on intramolecular
cyclization to liberate a drug substance and a lactam

5 derivative have been described where the liberated drugs
are alcohols, phenols, and primary and secondary amines.

For alcohols see, Saari et al., *J. Med. Chem.*, **33**, pp.

2590-2595 (1990). For phenols see, Saari et al., *J. Med.*

Chem., **33**, pp. 97-101 (1990). For amines see, Borchardt

10 et al., *Pharm. Sci.*, **86**, pp. 757-767 (1997).

[0125] Any of the preferred embodiments recited
herein, including those embodiments in the above species,
may define formula (I) individually or be combined to
produce a preferred embodiment of this invention.

15 **[0126]** Abbreviations which are used in the schemes,
preparations and the examples that follow are:

THF: tetrahydrofuran

DMF: N,N,-dimethylformamide

EtOAc: ethyl acetate

20 AcOH: acetic acid

NMM: N-methylmorpholine

NMP: N-methylpyrrolidinone

EtOH: ethanol

t-BuOH: tert-butanol

25 Et₂O: diethyl ether

DMSO: dimethyl sulfoxide

DCCA: dichloroacetic acid

DIEA: diisopropylethylamine

MeCN: acetonitrile

30 TFA: trifluoroacetic acid

DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene

DEAD: diethyl azodicarboxylate

HOBT: 1-hydroxybenzotriazole hydrate

HOAt: 1-hydroxy-7-azabenzotriazole

- EDC: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride
- Boc: tert-butyloxycarbonyl
- Boc₂O: di-tert-butyl dicarbonate
- 5 Cbz: benzyloxycarbonyl
- Cbz-Cl: benzyl chloroformate
- Fmoc: 9-fluorenyl methyloxycarbonyl
- SEM: silylethoxymethyl
- TBAF: tetrabutylammonium fluoride
- 10 Chg: cyclohexylglycine
- t-BG: *tert*-butylglycine
- mCBPA: 3-chloroperoxybenzoic acid
- DAST: (diethylamino)sulfur trifluoride
- TEMPO: 2,2,6,6-tetramethyl-1-piperidinyloxy, free radical
- 15 PyBOP: tris(pyrrolidino)bromophosphonium
hexafluorophosphate
- TBTU or HATU: 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium tetrafluoroborate
- DMAP: 4-dimethylaminopyridine
- 20 AIBN: 2,2'-azobisisobutyronitrile
- rt or RT: room temperature
- ON: overnight
- ND: not determined
- MS: mass spectrometry
- 25 LC: liquid chromatography

General Synthetic Methodology:

- [0127] The compounds of this invention may be prepared
- 30 in general by methods known to those skilled in the art.
Advantageously, these compounds are conveniently
synthesized from readily available starting materials.
Schemes 1-17 below illustrate synthetic routes to the
compounds of the present invention.


[0128] As can be appreciated by the skilled artisan, the synthetic schemes shown are not intended to comprise a comprehensive list of all means by which the compounds described and claimed in this application may be


5 synthesized. Other equivalent schemes, which will be readily apparent to the ordinary skilled organic chemist, may alternatively be used to synthesize various portions of the molecule as illustrated by the general schemes below. Additionally, the various synthetic steps

10 described above may be performed in an alternate sequence or order to give the desired compounds. Other equivalent schemes, which will be readily apparent to the ordinary skilled organic chemist, may alternatively be used to synthesize various portions of the molecule as

15 illustrated by the general schemes below, and the preparative examples that follow.

Scheme 1:








- 5 **[0129]** Scheme 1 above provides a general route for the preparation of compounds of formula **I** and **IA-1**, wherein V is -C(O), W is -C(O)C(O)-N(R₆)₂, R₂, R₄, and R₇ are H, and R₁, R₃, R₅, R_{5'}, R₆, R₉, R_{9'}, R₁₀, R_{10'}, R₁₁, R_{11'}, R₁₂, R_{12'}, R₁₄, R₁₅, R₁₆, R₁₈, R_{18'}, A, and U are as described in any
- 10 of the embodiments herein. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediates **3**, **5**, **7**, and **10**. Additionally, it will be

recognized that the commercially available Cbz protected amino acids represented by, for instance, Cbz-R₁-OH, may alternatively be substituted with the commercial t-Boc protected amino acids. Suitable deprotection conditions to remove the Boc protecting groups are known to those skilled in the art. Likewise the oxidation of intermediate **10** to compounds of formula **IA-1** may be accomplished using other suitable conditions known to the skilled artisan. Intermediate **2** may be prepared according to the procedures described by Schoellkopf, et al., *Justus Liebigs Ann. Chem.* GE, pp. 183-202 (1976) and Stemple et al., *Organic Letters*, **2(18)**, pp. 2769-2772 (2000). Intermediate pyrrole acid **9** may be prepared according to the methods described in the schemes below starting from commercially available starting materials.

Scheme 2:






[0130] Scheme 2 above provides a general route for the preparation of compounds of formula **I** and **IA-2** wherein V

is -C(O), W is -C(O)C(O)-N(R₆)₂, R₁₈ is absent and R_{18'} is =O, U is a bond, A is -C(R₁₂)(R_{12'})-T-R₁₃ wherein R₁₂ is absent, R_{12'} is =O, T is a bond and R₁₃ is R₁₉, R₁₉ is a (C1-C12)-aliphatic- with one carbon atom replaced by an NR₁₉ substituent, R₁₉ is hydrogen, x is preferably 2-4, R₂, R₄, and R₇ are H, and R₁, R₃, R₅, R_{5'}, R₆, R₉, R_{9'}, R₁₀, R_{10'}, R₁₁, R_{11'}, R₁₂, R_{12'}, R₁₄, R₁₅, and R₁₆ are as described in any of the embodiments herein. The preparation of compounds of formula **I** and **IA-2**, wherein R₁₃ is different than that depicted in scheme 2, may be accomplished in similar fashion by acylation of the pyrrole anion using other commercially available acid chlorides. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediate **14**. Likewise the oxidation of intermediate **14** may be accomplished using other suitable conditions known to the skilled artisan.


Scheme 3:




- 5 **[0131]** Scheme 3 above provides a general route for the preparation of compounds of formula **I** and **IA-3** wherein V is -C(O), W is -C(O)C(O)-N(R₆)₂, R₁₈ is absent and R_{18'} is =O, U is a bond, A is -C(R₁₂)(R_{12'})-T-R₁₃ wherein R₁₂ is hydrogen, R_{12'} is CH, T is oxygen and R₁₃ is -C(O)R', R₂, R₄, and R₇ are H, and R', R₁, R₃, R₅, R_{5'}, R₆, R₉, R_{9'}, R₁₀, R_{10'}, R₁₁, R_{11'}, R₁₂, R_{12'}, R₁₄, R₁₅, and R₁₆ are as described in any of the embodiments herein. Condensation of the pyrrole **16** with paraformaldehyde is accomplished according to the procedures listed in PCT publication WO
- 10

97/41132. The preparation of compounds of formula **I** and **IA-2**, wherein R_{12} is hydrogen, R_{12}' is (C2-C6)-aliphatic- may be accomplished in similar fashion by substituting the appropriate aldehyde for paraformaldehyde in the conversion of **16** to **17**. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediate **20**. Likewise the oxidation of intermediate **20** may be accomplished using other suitable conditions known to the skilled artisan.

Scheme 4:






[0132] Scheme 4 above provides a general route for the preparation of compounds of formula **I** and **IA-4** and **IA-5** wherein V is -C(O), W is -C(O)C(O)-N(R₆)₂, R₁₈ is absent and R_{18'} is =O, U is a bond, A is -C(R₁₂)(R_{12'})-T-R₁₃ wherein R₁₂ is hydrogen, R_{12'} is CH, T is oxygen and R₁₃ is -P(O)(OR')₂, R' is benzyl (**IA-4**) or hydrogen (**IA-5**), R₂, R₄, and R₇ are H, and R', R₁, R₃, R₅, R_{5'}, R₆, R₉, R_{9'}, R₁₀, R_{10'}, R₁₁, R_{11'}, R₁₂, R_{12'}, R₁₄, R₁₅, and R₁₆ are as described in any of the embodiments herein. Pyrrole alcohol **17** (prepared by methods described above in scheme 3) is converted to chloride **18** with thionyl chloride followed by displacement with potassium dibenzyl phosphate to give phosphate ester **22** all according to the procedures listed in PCT publication WO 97/41132. Mild acid hydrolysis of the t-butyl ester followed by the coupling conditions and oxidation described in scheme 3 above gives compound **IA-4**. Hydrogenolysis of dibenzyl ester **IA-4** using standard palladium catalysis gives free phosphonooxy acid **IA-5**. The preparation of compounds of formula **IA-4**, wherein R' is other than benzyl may be accomplished in similar fashion by using the appropriate phosphate reagent for


the conversion of **21** to **22**. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediate **24**. Likewise the oxidation of intermediate **24** and the hydrogenolysis of **IA-4** may be accomplished using other suitable conditions known to the skilled artisan.

Scheme 5:




[0133] Scheme 5 above provides a general route for the preparation of compounds of formula **I** and **IA-6** wherein V is -C(O), W is -C(O)C(O)-N(R₆)₂, R₁₈ is absent and R_{18'} is =N(OR'), U is a bond, R₁₆ is R', A is hydrogen, R₂, R₄, and R₇ are H, R', R₁, R₃, R₅, R_{5'}, R₆, R₉, R_{9'}, R₁₀, R_{10'}, R₁₁, R_{11'}, R₁₂, R_{12'}, R₁₄, and R₁₅, are as described in any of the embodiments herein. Pyrrole acid **25** (prepared by methods described above in scheme 3 and below in scheme 6) is esterfied to give SEM ester **26**. Protection of the pyrrole nitrogen according to the procedure in *J. Chem. Soc. Perkin Trans. 1*, pp. 2181-2186 (1986) provides intermediate **27**. Condensation with hydroxylamine (or alkylhydroxyl amine wherein R₁₈ is absent and R_{18'} is =N(OR')), accomplished according to the procedure in *J. Org. Chem.*, pp. 5917-5921 (1992), gives oxime **28**. TBAF deprotection of both silyl based protecting groups according to the procedure described in *J. Chem. Soc. Perkin Trans. (1)*, pp. 2181-2186 (1986), gives pyrrole oxime acid **29**. Final coupling and oxidation are accomplished according to the procedures listed above in schemes 1, 3, and 5. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediate **30**. Likewise the oxidation of intermediate **30** to **IA-6** may be accomplished using other suitable conditions known to the skilled artisan.


Scheme 6:



[0134] Scheme 6 above provides a general route for the preparation of starting pyrrole acid **35**, wherein R_{14} and R_{15} are methyl, A is H, R_{18} is absent, $\text{R}_{18'}$ is =O, U is a bond and R_{16} is methyl. It will be appreciated by those skilled in the art that other pyrrole analogs of interest may be synthesized by modifications of scheme 6.

10 Scheme 7:






- 5 **[0135]** Scheme 7 above provides a general route for the preparation of compounds of formula **I** and **IA-7** wherein V is -C(O), W is -C(O)C(O)-N(R₆)₂, R₁₈ is absent and R₁₈' is =N(R'), U is a bond, R₁₆ is R', A is hydrogen, R₂, R₄, and R₇ are H, R', R₁, R₃, R₅, R₅', R₆, R₉, R₉', R₁₀, R₁₀', R₁₁, R₁₁', R₁₂, R₁₂', R₁₄, and R₁₅, are as described in any of the
- 10 embodiments herein. Protected pyrrole ester **27** (prepared by methods described above in scheme 5 and scheme 6) is condensed with an appropriate amine, according to the procedure in *J. Chem. Soc. Chem. Commun.*, (6) pp. 634-635
- 15 (1986), to give imine **36**. TBAF deprotection of both silyl based protecting groups according to the procedure described in *J. Chem. Soc. Perkin Trans. (1)*, pp. 2181-2186 (1986), gives pyrrole imine acid **37**. Final coupling and oxidation are accomplished according to the
- 20 procedures listed above in schemes 1, 3, and 5. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used

to prepare intermediate **38**. Likewise the oxidation of intermediate **38** to **IA-7** may be accomplished using other suitable conditions known to the skilled artisan.

5 Scheme 8:



10

[0136] Scheme 8 above provides a general route for the preparation of compounds of formula **I** and **IA-8** wherein V

is $-C(O)$, W is $-C(O)C(O)-N(R_6)_2$, R_{18} is absent and $R_{18'}$ is $=CH_2$, U is nitrogen, R_{16} is R' wherein R' is acetyl, A is hydrogen, R_2 , R_4 , and R_7 are H, R_1 , R_3 , R_5 , R_5' , R_6 , R_9 , R_9' , R_{10} , $R_{10'}$, R_{11} , $R_{11'}$, R_{12} , $R_{12'}$, R_{14} , and R_{15} , are as described


5 in any of the embodiments herein. Condensation of **27** with hydroxylamine using the procedure described in *J. Org. Chem.*, pp. 5917-5921 (1992), gives oxime **39**. Oxime acylation with acetic anhydride followed by thermal rearrangement in pyridine, according to the procedure


10 described in *Leibigs Ann. Chem.*, (**12**), pp. 2065-2080 (1986), gives enamide **41**. TBAF deprotection of both silyl based protecting groups according to the procedure described in *J. Chem. Soc. Perkin Trans. (1)*, pp. 2181-2186 (1986), gives pyrrole acid **42**. Final coupling and

15 oxidation are accomplished according to the procedures listed above in schemes 1, 3, 5, and 7. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediate **43**. Likewise the oxidation of

20 intermediate **43** to **IA-8** may be accomplished using other suitable conditions known to the skilled artisan.

Scheme 9:







- 5 **[0137]** Scheme 9 above provides a general route for the preparation of compounds of formula **I**, **IA-9**, and **IA-10** wherein V is -C(O), W is -C(O)C(O)-N(R₆)₂, R₁₈ is absent and R_{18'} is =CH₂, U is oxygen, R₁₆ is -P(O)(OR')₂ wherein R' is benzyl (**IA-9**) or hydrogen (**IA-10**), A is hydrogen, R₂, R₄, and R₇ are H, R₁, R₃, R₅, R_{5'}, R₆, R₉, R_{9'}, R₁₀, R_{10'}, R₁₁, R_{11'}, R₁₂, R_{12'}, R₁₄, and R₁₅, are as described in any of the embodiments herein. The enolate of protected pyrrole ester **27** (prepared as described in the preceding schemes wherein R₁₆ is methyl) is generated with LDA and reacted with dibenzylchlorophosphate according to the method described in *Tet. Lett.*, pp. 4275-4277 (2003) to give enol phosphate **44**. It will be appreciated by those skilled in the art that other enol phosphates of interest may be prepared by the same procedure by adjusting the
- 10
- 15

starting chlorophosphate reagent used. TBAF deprotection of both silyl based protecting groups according to the procedure described in *J. Chem. Soc. Perkin Trans. (1)*, pp. 2181-2186 (1986), gives pyrrole acid **45**. Final coupling and oxidation are accomplished according to the procedures listed in any of the schemes above. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediate **46**. Hydrogenolysis of dibenzyl ester **1A-9** using standard palladium catalysis gives free enol phosphonooxy acid **1A-10**. Likewise the oxidation of intermediate **24** and the deprotection of **1A-9** may be accomplished using other suitable conditions known to the skilled artisan.

Scheme 10:



**IA-11**

[0138] Scheme 10 above provides a general route for the preparation of compounds of formula **I** and **IA-11**

5 wherein V is -C(O), W is -C(O)C(O)-N(R₆)₂, R₁₈ is absent and R_{18'} is =CH₂, U is oxygen, R₁₆ is -C(O)R', A is hydrogen, R₂, R₄, and R₇ are H, R₁, R₃, R₅, R_{5'}, R₆, R₉, R_{9'}, R₁₀, R_{10'}, R₁₁, R_{11'}, R₁₂, R_{12'}, R₁₄, R₁₅, and R₁₆, are as described in any of the embodiments herein. The enolate

10 of protected pyrrole ester **27** (prepared as described in the preceding schemes wherein R₁₆ is methyl) is generated with LDA and reacted with a suitable acyl chloride to give enol ester **47**. TBAF deprotection of both silyl based protecting groups according to the procedure


15 described in *J. Chem. Soc. Perkin Trans. (1)*, pp. 2181-2186 (1986), gives pyrrole acid **48**. Final coupling and oxidation are accomplished according to the procedures listed in any of the schemes above. As would be recognized by skilled practitioners, other suitable and

20 commercially available coupling reagents may be used to prepare intermediate **48**. Likewise the oxidation of intermediate **48** may be accomplished using other suitable conditions known to the skilled artisan. Enol ethers wherein R₁₈ is absent and R_{18'} is =CH₂, U is oxygen and R₁₆

25 is -R' may also be prepared according to the methods listed in scheme 10. For instance to prepare the enol ether analog wherein R₁₆ is methyl, the pyrrole enolate generated from LDA treatment of **27** could be reacted with

dimethyl sulfate and then carried through the same synthetic sequence described above.


Scheme 11:



[0139] Scheme 11 above provides a general route for the preparation of compounds of formula **I** and **IA-12** wherein V is -C(O), W is -C(O)C(O)-N(R₆)₂, are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated ring system; wherein the R₁₈ and R_{18'} atoms bound to the carbon atom are


O; U is a bond, R_{16} is $-R'$, A is hydrogen, R_2 , R_4 , and R_7 are H, R' , R_1 , R_3 , R_5 , R_5' , R_6 , R_9 , R_9' , R_{10} , R_{10}' , R_{11} , R_{11}' , R_{12} , R_{12}' , R_{14} , R_{15} , and R_{16} , are as described in any of the embodiments herein. The pyrrole nitrogen in intermediate **11** (prepared as described in the preceding schemes) is Boc protected under standard conditions to give BOC-protected pyrrole ester **50**. Acid catalyzed condensation with an appropriate diol according to the method described in *J. Org. Chem* pp. 2663-2669 (1984), gives ketal **52** which is hydrolyzed under basic conditions to give the pyrrole acid **53**. Final coupling and oxidation are accomplished according to the procedures listed in any of the schemes above. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediate **54**. Likewise the oxidation of intermediate **54** may be accomplished using other suitable conditions known to the skilled artisan.

Scheme 12:



[0140] Scheme 12 above in combination with scheme 1 above provides a general route for the preparation of compounds of formula **I** and **IH** wherein V is -C(O), W is -C(O)C(O)-N(R₆)₂, R₂, R₄, and R₇ are H, and R₁, R₃, R₅, R_{5'}, R₆, R₉, R_{9'}, R₁₁, R_{11'}, R₁₂, R_{12'}, R₁₄, R₁₅, R₁₆, R₁₈, R_{18'}, n, A, U, Z, and Z' are as described in any of the embodiments herein. Scheme 12 above in combination with scheme 1 also provides a general route for the preparation of compounds of formula **I** and **IK** using modifications (e.g. other appropriate commercially available starting materials) known to those skilled in the art.


Scheme 13:



15

[0141] Scheme 13 above in combination with scheme 1 above provides a general route for the preparation of compounds of formula **I** and **IK** wherein V is -C(O), W is -C(O)C(O)-N(R₆)₂, R₂, R₄, and R₇ are H, R₁₀, and R_{10'} are fluoro, and R₁, R₃, R₅, R_{5'}, R₆, R₉, R_{9'}, R₁₁, R_{11'}, R₁₂, R_{12'}, R₁₄, R₁₅, R₁₆, R₁₈, R_{18'}, A, and U, are as described in any of the embodiments herein.

Scheme 14:





[0142] Scheme 14 above provides a general route for the preparation of compounds of formula **I**, **IL**, and **IL-1**

wherein V is -C(O), W is -C(O)C(O)-N(R₆)₂, R₂, R₄, R₇, R₉,

R_9 , R_{10} , R_{11} , and $R_{11'}$, are H, $R_{10'}$ is OR' , and R_1 , R_3 , R_5 , R_5' , R_6 , R_{14} , R_{15} , R_{16} , R_{18} , $R_{18'}$, A, and U, are as described in any of the embodiments herein. As would be appreciated by any skilled practitioner, compound **67** may be carried on to compounds of formula **II-1** by routine methods. Additionally, other suitable and commercially available coupling reagents may be used to prepare intermediates **64**, **65**, **67**, and **68**. Likewise, the oxidation of intermediate **68** to compounds of formula **II-1** may be accomplished using other suitable conditions known to the skilled artisan.


Scheme 15:






[0143] Scheme 15 above, depicts an alternative approach to preparing compounds of formula **IL** and **IL-1** of this invention wherein V is $-\text{C}(\text{O})$, W is $-\text{C}(\text{O})\text{C}(\text{O})-\text{N}(\text{R}_6)_2$, R_2 , R_4 , R_7 , R_9 , R_9' , R_{10}' , R_{11} , and R_{11}' , are H, R_{10}' is OR' , and R_1 , R_3 , R_5 , R_5' , R_6 , R_{14} , R_{15} , R_{16} , R_{18} , R_{18}' , A, and U, are as described in any of the embodiments herein. In this approach, a 4-hydroxyproline derivative **69** is reacted with a commercially available R' -halide (such an aryl chloride), represented by $\text{R}'\text{-X}$, in the presence of a suitable base (such as potassium t-butoxide) to provide a compound **70**. As would be appreciated by any skilled practitioner, compound **70** may be carried on to compounds of formula **IE-1** by routine methods. Additionally, other suitable and commercially available coupling reagents may be used to prepare intermediates **72**, **73**, **74**, and **75**. Likewise, the oxidation of intermediate **75** to compounds of formula **IL-1** may be accomplished using other suitable conditions known to the skilled artisan.

Scheme 16:



**IM-1**


[0144] Scheme 16 in combination with scheme 1 above provides a general route for the preparation of compounds of formula **IM**, and **IM-1** wherein V is -C(O), W is -

5 C(O)C(O)-N(R₆)₂, R₂, R₄, R₇, R₉, R_{9'}, R_{10'}, and R_{11'}, are H, R₁₀ and R₁₁ are taken together with the ring atoms to which they are bound to form a ring system as defined in any of the embodiments and R₁, R₃, R₅, R_{5'}, R₆, R₁₄, R₁₅, R₁₆, R₁₈, R_{18'}, A, and U, are as described in any of the
10 embodiments herein. Bicyclic starting materials such as compound **76** may be any commercially available reagents of interest or may be synthesized according to literature methods known to the skilled artisan. After coupling of **76** to intermediate **2**, resulting intermediate **80** may be
15 carried on to compounds of formula **IM-1** by the methods described in scheme 1. Scheme 16 in combination with scheme 1

[0145] Compounds of this invention represented by formula **IN** may also be prepared from commercially
20 available amino acid derivatives by the route described in schemes 1 and 16 above. If a starting amino acid analogue of interest is not commercially available it may be prepared according to literature methods known to those skilled in the art.

25

Scheme 17:



[0146] Scheme 17 above provides a synthetic route for the preparation of Cbz-protected azabicyclo[2.2.1]heptane-3-carboxylic acid, compound **83** and the corresponding t-butyl ester, compound **84**. The free acid **83** may be further elaborated by the route defined in scheme 1 above to prepare compounds of formula **I** and **IO**.

[0147] The preparation of various other optionally substituted multicyclic azaheterocyclis intermediates to prepare compounds of formulae **I** and **IN** via schemes 1, 14 or 15 above, may be accomplished by the methods described in PCT publication No. WO 02/18369 and references cited therein.

[0148] Various 3, 4, and 5-substituted proline analogues may either be purchased commercially or prepared according to known literature procedures. For instance, for compounds of formula **I** wherein R₉ is (C1-C12)-aliphatic-, the starting 3-substituted proline analogues may be prepared according to the method of

Holladay, M.W. et al., *J. Med. Chem.*, **34**, pp. 457-461 (1991). For compounds of formula **I** wherein either R₉, R₁₀, or R₁₁ are cyclohexyl and R₉, R₁₀, or R₁₁ are hydrogen, the cyclohexyl proline intermediates may be prepared by platinum oxide reduction of the commercially available phenyl substituted proline analogues. Such reduction conditions are well known to those skilled in the art.

For compounds of formula **I** wherein R₉ is

(C1-C12)-aliphatic- and R₁₀ is (C1-C12)-aliphatic-, the


starting 3,4-disubstituted proline analogues may be prepared according to the method of Kanamasa, S. et al.,

J. Org. Chem., **56**, pp. 2875-2883 (1991). In each of the syntheses involving 3, 4, or 5-substituted prolines or

3,4-disubstituted prolines, the intermediates may be


further elaborated by the routes defined above in schemes 1, 14, or 15 to prepare compounds of formula **I**.

[0149] Accordingly, one embodiment of this invention provides a process for preparing a compound of formula **I**, as defined in any of the embodiments herein, comprising the step of: reacting a compound of formula VII in the presence of a compound of formula VIII to provide a compound of formula IX:



VII

R'X



IX

wherein:

R₂₁ is an amine protecting group, a P3- residue of an HCV protease inhibitor described herein, or a P4-P3- residue of an HCV protease inhibitor as described herein, and wherein the P3 and the P4-P3 residues are optionally protected with an amino-terminal capping group;

R₂₀ is a carboxy protecting group or a P1 residue of an HCV protease inhibitor described herein, wherein the P1 residue is optionally protected with a carboxy terminal protecting group or with W. R' is as defined in any of the embodiments herein. X is an appropriate leaving group. As would be appreciated by skilled practitioners, an appropriate leaving group may be generated in situ.

[0150] In an alternative embodiment, the 4-hydroxy group in formula VII may be converted to a leaving group.

10 In such an embodiment, X is a nucleophilic oxygen which reacts with VII to provide IX.

[0151] As used herein, P1, P3, P4 refer to the residues of an HCV protease inhibitor as defined in the art and as are well known to skilled practitioners.

15 **[0152]** The compound of formula IX may be carried on to a compound of formula I according to the methods described herein.

[0153] Although certain exemplary embodiments are depicted and described below, it will be appreciated that 20 compounds of this invention can be prepared according to the methods described generally above using appropriate starting materials generally available to one of ordinary skill in the art.

[0154] Another embodiment of this invention provides a 25 pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof. According to a preferred embodiment, the compound of formula I is present in an amount effective to decrease the viral load in a sample or in a patient, wherein said 30 virus encodes a serine protease necessary for the viral life cycle, and a pharmaceutically acceptable carrier.

[0155] If pharmaceutically acceptable salts of the compounds of this invention are utilized in these compositions, those salts are preferably derived from

inorganic or organic acids and bases. Included among such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentane-propionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenyl-propionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.

[0156] Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.

[0157] The compounds utilized in the compositions and methods of this invention may also be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system

(e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.

5 **[0158]** Pharmaceutically acceptable carriers that may be used in these compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic
10 acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium
15 trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

20 **[0159]** According to a preferred embodiment, the compositions of this invention are formulated for pharmaceutical administration to a mammal, preferably a human being.

25 **[0160]** Such pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular,
30 intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally or intravenously.

[0161] Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.

[0162] Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day of the protease inhibitor compounds described herein are useful

in a monotherapy for the prevention and treatment of antiviral, particularly anti-HCV mediated disease. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Preferably, such preparations contain from about 20% to about 80% active compound.

[0163] When the compositions of this invention comprise a combination of a compound of formula I and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 10 to 100%, and more preferably between about 10 to 80% of the dosage normally administered in a monotherapy regimen.

[0164] The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers that are commonly used include lactose and corn starch.

Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

[0165] Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These may be prepared by mixing the agent with a suitable
5 non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

10 **[0166]** The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal
15 tract. Suitable topical formulations are readily prepared for each of these areas or organs.

[0167] Topical application for the lower intestinal tract may be effected in a rectal suppository formulation (see above) or in a suitable enema formulation.

20 Topically-transdermal patches may also be used.

[0168] For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical
25 administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical
30 compositions may be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60,

cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

[0169] For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions
5 in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated
10 in an ointment such as petrolatum.

[0170] The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical
15 formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

20 **[0171]** Most preferred are pharmaceutical compositions formulated for oral administration.

[0172] In one embodiment, the compositions of this invention additionally comprise another agent, preferably a cytochrome P-450 inhibitor. Such cytochrome P-450
25 inhibitors include, but are not limited to, ritonavir.

[0173] In another embodiment, the compositions of this invention additionally comprise another anti-viral agent, preferably an anti-HCV agent. Such anti-viral agents include, but are not limited to, immunomodulatory agents,
30 such as α -, β -, and γ -interferons, pegylated derivatized interferon- α compounds, and thymosin; other anti-viral agents, such as ribavirin, amantadine, and telbivudine; other inhibitors of hepatitis C proteases (NS2-NS3 inhibitors and NS3-NS4A inhibitors); inhibitors of other

targets in the HCV life cycle, including helicase and polymerase inhibitors; inhibitors of internal ribosome entry; broad-spectrum viral inhibitors, such as IMPDH inhibitors (e.g., VX-497 and other IMPDH inhibitors disclosed in United States Patents 5,807,876 and 6,498,178, mycophenolic acid and derivatives thereof); inhibitors of cytochrome P-450, such as ritonavir, or combinations of any of the above.

[0174] Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

[0175] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of active ingredients will also depend upon the particular described compound and the presence or absence and the nature of the additional anti-viral agent in the composition.

[0176] According to another embodiment, the invention provides a method for treating a patient infected with a virus characterized by a virally encoded serine protease that is necessary for the life cycle of the virus by

administering to said patient a pharmaceutically acceptable composition of this invention. Preferably, the methods of this invention are used to treat a patient suffering from a HCV infection. Such treatment may
5 completely eradicate the viral infection or reduce the severity thereof. More preferably, the patient is a human being.

[0177] In an alternate embodiment, the methods of this invention additionally comprise the step of administering
10 to said patient an anti-viral agent preferably an anti-HCV agent. Such anti-viral agents include, but are not limited to, immunomodulatory agents, such as α -, β -, and γ -interferons, pegylated derivatized interferon- α compounds, and thymosin; other anti-viral agents, such as
15 ribavirin, amantadine, and telbivudine; other inhibitors of hepatitis C proteases (NS2-NS3 inhibitors and NS3-NS4A inhibitors); inhibitors of other targets in the HCV life cycle, including but not limited to helicase and polymerase inhibitors; inhibitors of internal ribosome
20 entry; broad-spectrum viral inhibitors, such as IMPDH inhibitors (e.g., VX-497 and other IMPDH inhibitors disclosed in United States Patents 5,807,876 and 6,498,178, mycophenolic acid and derivatives thereof); inhibitors of cytochrome P-450, such as ritonavir, or
25 combinations of any of the above.

[0178] Such additional agent may be administered to said patient as part of a single dosage form comprising both a compound of this invention and an additional anti-viral agent. Alternatively the additional agent may be
30 administered separately from the compound of this invention, as part of a multiple dosage form, wherein said additional agent is administered prior to, together with or following a composition comprising a compound of this invention.

[0179] In yet another embodiment the present invention provides a method of pre-treating a biological substance intended for administration to a patient comprising the step of contacting said biological substance with a pharmaceutically acceptable composition comprising a compound of this invention. Such biological substances include, but are not limited to, blood and components thereof such as plasma, platelets, subpopulations of blood cells and the like; organs such as kidney, liver, heart, lung, etc; sperm and ova; bone marrow and components thereof, and other fluids to be infused into a patient such as saline, dextrose, etc.

[0180] According to another embodiment the invention provides methods of treating materials that may potentially come into contact with a virus characterized by a virally encoded serine protease necessary for its life cycle. This method comprises the step of contacting said material with a compound according to the invention. Such materials include, but are not limited to, surgical instruments and garments (e.g. clothes, gloves, aprons, gowns, masks, eyeglasses, footwear, etc.); laboratory instruments and garments (e.g. clothes, gloves, aprons, gowns, masks, eyeglasses, footwear, etc.); blood collection apparatuses and materials; and invasive devices, such as shunts, stents, etc.

[0181] In another embodiment, the compounds of this invention may be used as laboratory tools to aid in the isolation of a virally encoded serine protease. This method comprises the steps of providing a compound of this invention attached to a solid support; contacting said solid support with a sample containing a viral serine protease under conditions that cause said protease to bind to said solid support; and eluting said serine protease from said solid support. Preferably, the viral

serine protease isolated by this method is HCV NS3-NS4A protease.

[0182] In order that this invention be more fully understood, the following preparative and testing examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.

EXAMPLES

[0183] ¹H-NMR spectra were recorded at 500 MHz using a Bruker AMX 500 instrument. Mass spec. samples were analyzed on a MicroMass ZQ or Quattro II mass spectrometer operated in single MS mode with electrospray ionization. Samples were introduced into the mass spectrometer using flow injection (FIA) or chromatography. Mobile phase for all mass spec. analysis consisted of acetonitrile-water mixtures with 0.2% formic acid as a modifier.

[0184] As used herein, the term "R_t(min)" refers to the HPLC retention time, in minutes, associated with the compound. The HPLC retention times listed were either obtained from the mass spec. data or using the following method:

Instrument: Hewlett Packard HP-1050;

[0185] Column: YMC C₁₈ (Cat. No. 326289C46);

Gradient/Gradient Time: 10-90% CH₃CN/H₂O over 9 minutes,
then 100% CH₃CN for 2 minutes;

Flow Rate: 0.8ml/min;

Detector Wavelength: 215nm and 245nm.

[0185] Chemical naming for selected compounds herein was accomplished using the naming program provided by CambridgeSoft Corporations ChemDraw Ultra®, version 7.0.1.

Example 1**3-Acetyl-4,5-dimethyl-2-pyrrole carboxylic acid (35).**

[0186] A solution of sodium nitrite (36.9 g, 0.534 mol) in 70 mL of water was added dropwise to a stirred solution of ethylacetoacetate (70 g, 0.538 mol) in 1401 mL of glacial acetic acid at 0°C. After the addition was complete, the light yellow reaction mixture was allowed to warm to room temperature. After 30 minutes, all the starting material had been consumed, the reaction was quenched with 350 mL of water and extracted with ethyl acetate (2 X 125 mL). The organic extracts were combined and washed with water (2 X 125 mL) and saturated sodium hydrogen carbonate aqueous solution (2 X 105 mL). The organic layer was dried with sodium sulfate and concentrated *in vacuo* to give 84.2 g (98%) of ethyl-2-hydroxyimino-3-oxobutanoate **31** as a pale yellow oil. ¹H NMR (CDCl₃) δ 10.3 (s, 1H), 4.2 (q, 2H), 2.3 (s, 3H), 1.3 (t, 3H) ppm.

[0187] Crushed sodium (12.4 g, 0.540 mol) was added to a solution of 2-butanone (48.2 mL, 0.538 mol) and ethyl formate (43.47 mL, 0.538 mol) in dry ether (540 mL) with vigorous mechanical stirring over a period of 1 h, during which time the mixture was chilled in an ice-salt bath. The mixture was then stirred at room temp. for 14 h. After cooling the reaction mixture to 4°C for a few hours, the precipitated sodium salt was obtained by filtration and washed thoroughly with cold, dry ether to afford 49.3 g (75%) of the desired sodium salt of 2-Methy-3-oxobutyraldehyde **32**. ¹H NMR (DMSO-d₆) δ 9.1 (s, 1H), 1.9 (s, 3H), 1.3 (s, 3H) ppm.

[0188] Sodium salt **32** (49.3 g, 0.404 mol) and oxime **31** (64.23, 0.404 mol) were stirred in 300 mL of 70% acetic acid/ 30% water and warmed to 50°C. Zinc powder (42.21 g, 0.646 mol) was added portion-wise over 30 minutes

maintaining the temperature below 100°C. When the addition was complete, the suspension was refluxed for 15 minutes, then poured into 4 L of ice-water. After a short time, the product precipitated out to give, after
5 filtration, 30.1 g (45%) of the desired ethyl-4,5-dimethyl-2-pyrrole carboxylate **33**. ¹H NMR (CDCl₃) δ 9.0 (bs, 1H), 6.7 (s, 1H), 4.3 (q, 2H), 2.3 (s, 3H), 2.0 (s, 3H), 1.3 (t, 3H) ppm.


[0189] To a solution of aluminum chloride (50.19 g, 0.376 mol) in dry dichloroethane (580 mL) at 25°C was
10 added slowly acetic anhydride (17.75 mL, 0.188 mol). The resulting mixture was stirred at room temp. for 10 minutes, then a solution of pyrrole **33** (10.49 g, 0.0627 mol) in dichloroethane (30 mL) was added and the reaction
15 mixture was stirred at room temp. for 2h. After an additional 3h at 80°C, the mixture was poured into ice water and extracted with dichloromethane. The organic layer was dried with anhy. sodium sulfate and concentrated *in vacuo* to an orange residue. Short plug filtration over
20 silica gel (30% ethyl acetate / 70% hexanes) gave 7.5 g (60%) of ethyl-3-acetyl-4,5-dimethyl-2-pyrrole carboxylate **34**. ¹H NMR (CDCl₃) δ 9.0 (bs, 1H), 4.3 (q, 2H), 2.7 (s, 3H), 2.1 (s, 3H), 1.9 (s, 3H), 1.3 (t, 3H) ppm.

[0190] A mixture of pyrrole ester **34** (8.2 g, 0.0392
25 mol), in ethanol and 100 mL of 10% potassium hydroxide were refluxed for 1 h. The mixture was cooled and concentrated *in vacuo* to an oil. Water was added to the oil, the mixture acidified with dilute HCl and extracted with ether. The organic phase was dried with anhy. sodium
30 sulfate and concentrated *in vacuo* to a solid residue. The compound was recrystallized in 80 mL of ethanol to give 5.8 g of pure 3-acetyl-4,5-dimethyl-2-pyrrole carboxylic acid **35** as a solid. ¹H NMR (DMSO-d₆) δ 2.5 (s, 3H), 2.2 (s, 3H), 2.0 (s, 3H) ppm.

CLAIMS

We claim:

1. A compound of formula I:



I

or a pharmaceutically acceptable salt thereof,
wherein:

R₉ and R₉' are each independently:

hydrogen-,

(C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-,

[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
aliphatic-,

(C6-C10)-aryl-,

(C6-C10)-aryl-(C1-C12)aliphatic-,

(C3-C10)-heterocyclyl-,

(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,

(C5-C10)-heteroaryl-, or

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to three aliphatic carbon atoms in each
of R₉ and R₉' are optionally replaced by O, N, NH, S,
SO, or SO₂ in a chemically stable arrangement;

wherein each of R₉ and R₉' is independently and
optionally substituted with up to 3 substituents
independently selected from J;

J is halogen, -OR', -NO₂, -CN, -CF₃, -OCF₃, -R', oxo,
thioxo, =N(R'), =N(OR'), 1,2-methylenedioxy, 1,2-
ethylenedioxy, -N(R')₂, -SR', -SOR', -SO₂R', -SO₂N(R')₂,

$-\text{SO}_3\text{R}'$, $-\text{C}(\text{O})\text{R}'$, $-\text{C}(\text{O})\text{C}(\text{O})\text{R}'$, $-\text{C}(\text{O})\text{C}(\text{O})\text{OR}'$,
 $-\text{C}(\text{O})\text{C}(\text{O})\text{N}(\text{R}')_2$, $-\text{C}(\text{O})\text{CH}_2\text{C}(\text{O})\text{R}'$, $-\text{C}(\text{S})\text{R}'$, $-\text{C}(\text{S})\text{OR}'$,
 $-\text{C}(\text{O})\text{OR}'$, $-\text{OC}(\text{O})\text{R}'$, $-\text{C}(\text{O})\text{N}(\text{R}')_2$, $-\text{OC}(\text{O})\text{N}(\text{R}')_2$,
 $-\text{C}(\text{S})\text{N}(\text{R}')_2$, $-(\text{CH}_2)_{0-2}\text{NHC}(\text{O})\text{R}'$, $-\text{N}(\text{R}')\text{N}(\text{R}')\text{COR}'$,
 $-\text{N}(\text{R}')\text{N}(\text{R}')\text{C}(\text{O})\text{OR}'$, $-\text{N}(\text{R}')\text{N}(\text{R}')\text{CON}(\text{R}')_2$, $-\text{N}(\text{R}')\text{SO}_2\text{R}'$,
 $-\text{N}(\text{R}')\text{SO}_2\text{N}(\text{R}')_2$, $-\text{N}(\text{R}')\text{C}(\text{O})\text{OR}'$, $-\text{N}(\text{R}')\text{C}(\text{O})\text{R}'$,
 $-\text{N}(\text{R}')\text{C}(\text{S})\text{R}'$, $-\text{N}(\text{R}')\text{C}(\text{O})\text{N}(\text{R}')_2$, $-\text{N}(\text{R}')\text{C}(\text{S})\text{N}(\text{R}')_2$,
 $-\text{N}(\text{COR}')\text{COR}'$, $-\text{N}(\text{OR}')\text{R}'$, $-\text{C}(=\text{NH})\text{N}(\text{R}')_2$, $-\text{C}(\text{O})\text{N}(\text{OR}')\text{R}'$,
 $-\text{C}(=\text{NOR}')\text{R}'$, $-\text{OP}(\text{O})(\text{OR}')_2$, $-\text{P}(\text{O})(\text{R}')_2$, $-\text{P}(\text{O})(\text{OR}')_2$, or
 $-\text{P}(\text{O})(\text{H})(\text{OR}')$; wherein;

each R' is independently selected from:

hydrogen-,
 (C1-C12)-aliphatic-,
 (C3-C10)-cycloalkyl- or -cycloalkenyl-,
 [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
 aliphatic-,
 (C6-C10)-aryl-,
 (C6-C10)-aryl-(C1-C12)aliphatic-,
 (C3-C10)-heterocyclyl-,
 (C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
 (C5-C10)-heteroaryl-, and
 (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 5 atoms in R' are optionally and independently substituted with J;

wherein two R' groups bound to the same atom
 optionally form a 5- to 6-membered aromatic or a 3-
 to 7-membered saturated or partially unsaturated
 ring system having up to 3 heteroatoms independently
 selected from N, NH, O, S, SO, and SO₂, wherein said
 ring is optionally fused to a (C6-C10)aryl,
 (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a
 (C3-C10)heterocyclyl, wherein any ring has up to 3
 substituents selected independently from J;

R₁₀, R_{10'}, R₁₁, and R_{11'} are each independently:

hydrogen-,
 (C1-C12)-aliphatic-,
 (C3-C10)-cycloalkyl- or -cycloalkenyl-,
 [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
 aliphatic-,
 (C6-C10)-aryl-,
 (C6-C10)-aryl-(C1-C12)aliphatic-,
 (C3-C10)-heterocyclyl-,
 (C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
 (C5-C10)-heteroaryl-, or
 (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein any ring is optionally fused to a
 (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl,
 or (C3-C10)heterocyclyl;

wherein up to 3 aliphatic carbon atoms in each of
 R_{10} , $R_{10'}$, R_{11} , and $R_{11'}$ are optionally replaced by a
 heteroatom selected from O, NH, S, SO, or SO₂ in a
 chemically stable arrangement;

wherein each of R_{10} , $R_{10'}$, R_{11} , and $R_{11'}$ is
 independently and optionally substituted with up to 3
 substituents independently selected from J; or

R_{10} is -OR' and $R_{10'}$ is H; or

R_{10} and $R_{10'}$ are both -OR' or -SR'; or

R_{10} and $R_{10'}$ are both fluorine; or

R_{10} and $R_{10'}$ are optionally taken together with the carbon
 atom to which they are bound to form a 5- to 7-membered
 saturated or partially unsaturated ring system;

wherein the R_{10} and $R_{10'}$ atoms bound to the carbon
 atom are independently C(H), N, NH, O, S, SO, or SO₂;

wherein said ring optionally contains up to 4
 heteroatoms independently selected from N, NH, O, S,
 SO, and SO₂;

wherein any atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; and

wherein said ring is optionally fused to a second ring selected from (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, and a (C3-C10)heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; or

R₉ and R₁₀ are optionally taken together with the ring atoms to which they are bound to form a 5- to 6-membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system up to 3 heteroatoms independently selected from N, NH, O, S, SO, or SO₂; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; or

R₁₀ and R₁₁ are optionally taken together with the ring atoms to which they are bound to form a 5- to 6-membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3 heteroatoms independently selected from N, NH, O, S, SO, or SO₂; wherein said ring is optionally substituted with up to 3 substituents selected independently from J; or

R₉ and R₁₁ are optionally taken together with the ring atoms to which they are bound to form a bridged bicyclic saturated or partially unsaturated carbocyclic or heterocyclic ring system containing up to 10 atoms; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; wherein each heteroatom in the heterocyclic ring system is selected from the group consisting of N, NH, O, S, SO, or SO₂;

R₁ and R₃ are each independently:
(C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl- or -cycloalkenyl]-(C1-C12)-
aliphatic-,
(C6-C10)-aryl-(C1-C12)aliphatic-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 3 aliphatic carbon atoms in each of R₁ and R₃ are optionally replaced by a heteroatom selected from O, N, NH, S, SO, or SO₂ in a chemically stable arrangement;

wherein each of R₁ and R₃ is independently and optionally substituted with up to 3 substituents independently selected from J;

R₂, R₄, and R₇ are each independently:

hydrogen-,
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl-(C1-C12)-aliphatic-, or
(C6-C10)-aryl-(C1-C12)-aliphatic-;

wherein up to two aliphatic carbon atoms in each of R₂, R₄, and R₇ are optionally replaced by a heteroatom selected from O, N, NH, S, SO, and SO₂ in a chemically stable arrangement;


wherein each of R₂, R₄, and R₇ is optionally substituted with up to 3 substituents independently selected from J;


R₅ and R_{5'} are each independently hydrogen or (C1-C12)-aliphatic, wherein any hydrogen is optionally replaced with halogen; wherein any terminal carbon atom of R₅ is optionally substituted with sulfhydryl or hydroxy; or R₅ is Ph or -CH₂Ph and R_{5'} is H, wherein said Ph or -CH₂Ph group is optionally substituted with up to 3 substituents independently selected from J; or

R₅ and R_{5'} together with the atom to which they are bound optionally form a 3- to 6-membered saturated or partially unsaturated ring having up to 2 heteroatoms

selected from N, NH, O, SO, and SO₂; wherein said ring is optionally substituted with up to 2 substituents selected independently from J;

W is:





wherein m is 0 or 1;

wherein each R_6 is independently:

hydrogen-,

(C1-C12)-aliphatic-,

(C6-C10)-aryl-,

(C6-C10)-aryl-(C1-C12)aliphatic-,

(C3-C10)-cycloalkyl- or cycloalkenyl-,

[(C3-C10)-cycloalkyl- or cycloalkenyl]-(C1-C12)-aliphatic-,

(C3-C10)-heterocyclyl-,

(C3-C10)-heterocyclyl-(C1-C12)-aliphatic-,

(C5-C10)-heteroaryl-, or

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 3 aliphatic carbon atoms in each R_6 is optionally replaced by a heteroatom selected from O, NH, S, SO, or SO₂ in a chemically stable arrangement;

wherein R_6 is optionally substituted with up to 3 J substituents; or

two R_6 groups, together with the nitrogen atom to which they are bound, optionally form a 5- to 6-membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3 heteroatoms independently selected from N, NH, O, S, SO, and SO₂, wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J;

wherein each R_8 is independently -OR'; or the R_8 groups together with the boron atom, is a (C3-C10)-membered heterocyclic ring having in addition to the

boron up to 3 additional heteroatoms selected from N, NR', O, SO, and SO₂;

V is -C(O)-, -C(S)-, -S(O)-, or -S(O)₂-;

A is hydrogen or -C(R₁₂)(R_{12'})-T-R₁₃;

T is oxygen or a bond;

R₁₂ and R_{12'} are each independently:

hydrogen-, or

(C1-C6)-aliphatic-;

wherein up to two aliphatic carbon atoms in each of R₁₂ and R_{12'} are optionally replaced by a heteroatom selected from O, N, NH, S, SO, and SO₂ in a chemically stable arrangement; or

R₁₂ is absent and R_{12'} is =O;

R₁₃ is -C(O)R', -P(O)(OR')₂, -SO₃R', -R', or R₁₉;

R₁₉ is:

hydrogen,

(C1-C12)-aliphatic-,

(C6-C10)-aryl-(C1-C12)aliphatic-, or

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 3 aliphatic carbon atoms in each R₁₉ is optionally replaced by a heteroatom selected from O, NR₁₉, S, SO, or SO₂ in a chemically stable arrangement;

wherein up to 3 aliphatic carbon atoms in each R₁₉ is optionally replaced with -C(O)-;

wherein R₁₉ is optionally substituted with up to 3 J substituents;

wherein any NR₁₉, taken together with the nitrogen and a carbon adjacent to the nitrogen, optionally forms a 5- to 7-membered ring system, wherein said ring system optionally contains up to three additional heteroatoms selected from O, N, NH, S, SO, and SO₂ in a chemically stable arrangement;

R₁₄ and R₁₅ are independently halogen, -OR', -OC(O)N(R')₂, -NO₂, -CN, -CF₃, -OCF₃, -R', 1,2-methylenedioxy, 1,2-

ethylenedioxy, $-N(R')_2$, $-SR'$, $-SOR'$, $-SO_2R'$, $-SO_2N(R')_2$,
 $-SO_3R'$, $-C(O)R'$, $-C(O)C(O)R'$, $-C(O)CH_2C(O)R'$, $-C(S)R'$,
 $-C(O)OR'$, $-OC(O)R'$, $-C(O)N(R')_2$, $-OC(O)N(R')_2$,
 $-C(S)N(R')_2$, or $-(CH_2)_{0-2}NHC(O)R'$;

R_{16} is R' , $-C(O)R'$, $-P(O)(OR')_2$, or $-SO_3R'$;

U is O, N, or a bond; and

R_{18} and $R_{18'}$ are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system;

wherein the R_{18} and $R_{18'}$ atoms bound to the carbon atom are independently O or N;

wherein said ring optionally contains up to 1 additional heteroatom selected from N, NH, O, S, SO, and SO_2 ;

wherein any substitutable atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J;

wherein said ring is optionally fused to a second ring selected from (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, and a (C3-C10)heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J;

provided that when R_{18} and $R_{18'}$ are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system, then R_{16} is R' ; or

$R_{18'}$ is $=O$, $=CH_2$, $=N(R')$, or $=N(OR')$ and R_{18} is absent, provided that when R_{18} is absent and $R_{18'}$ is $=CH_2$, then U is oxygen; and

provided that when R_{18} is absent and $R_{18'}$ is $=O$, $=N(R')$ or $=N(OR')$, then U is a bond and R_{16} is R' .

2. The compound according to claim 1, wherein V is $-C(O)-$.

3. The compound according to claim 2, wherein:

A is $-C(R_{12})(R_{12'})-T-R_{13}$;

R_{12} and $R_{12'}$ are both hydrogen;

T is oxygen;

R_{13} is $-C(O)R'$, $-P(O)(OR')_2$, $-SO_3R'$, or $-R'$;

R_{14} and R_{15} are both $-R'$;

$R_{18'}$ is $=O$ and R_{18} is absent;

U is a bond; and

R_{16} is R' , wherein R' is selected from:

(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
aliphatic-;

wherein up to 5 atoms in R' are optionally and
independently substituted with J.

4. The compound according to claim 3, wherein:

R_{13} is $-C(O)R'$, $-P(O)(OR')_2$, or $-R'$;

R_{14} and R_{15} are both $-R'$ and R' is (C1-C12)-aliphatic-; and

R_{16} is R' , wherein R' is (C1-C12)-aliphatic-.

5. The compound according to claim 2, wherein:

A is $-C(R_{12})(R_{12'})-T-R_{13}$;

R_{12} is hydrogen and $R_{12'}$ is (C1-C6)-aliphatic-;

wherein up to two aliphatic carbon atoms in $R_{12'}$ are
optionally replaced by a heteroatom selected from O, N,
NH, S, SO, and SO_2 in a chemically stable arrangement;

T is oxygen;

R_{13} is $-C(O)R'$, $-P(O)(OR')_2$, $-SO_3R'$, or $-R'$;

R_{14} and R_{15} are both $-R'$;

$R_{18'}$ is $=O$ and R_{18} is absent;

U is a bond; and

R_{16} is R' , wherein R' is selected from:

(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
aliphatic-;

wherein up to 5 atoms in R' are optionally and
independently substituted with J.

6. The compound according to claim 5, wherein:
R₁₃ is -C(O)R', -P(O)(OR')₂, or -R';
R₁₄ and R₁₅ are both -R' and R' is (C1-C12)-aliphatic-;
R₁₆ is R', wherein R' is (C1-C12)-aliphatic-;

7. The compound according to claim 2, wherein:
A is -C(R₁₂)(R_{12'})-T-R₁₃;
R₁₂ is absent and R_{12'} is =O;
T is oxygen or a bond;
R₁₃ is -R₁₉;
R₁₄ and R₁₅ are both -R';
R_{18'} is =O and R₁₈ is absent;
U is a bond; and
R₁₆ is R', wherein R' is selected from:

(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
aliphatic-;

wherein up to 5 atoms in R' are optionally and
independently substituted with J.

8. The compound according to claim 2, wherein:
R_{18'} is =CH₂, and R₁₈ is absent;
U is oxygen;
R₁₆ is R', -C(O)R', -P(O)(OR')₂, or -SO₃R';
R₁₄ and R₁₅ are both -R'; and
A is hydrogen.

9. The compound according to claim 8, wherein:

R₁₆ is R', -C(O)R', or -P(O)(OR')₂;

R₁₄ and R₁₅ are both -R' and R' is (C1-C12)-aliphatic-.

10. The compound according to claim 2, wherein:

R₁₈' is =N(R') or =N(OR') and R₁₈ is absent;

5 U is a bond;

R₁₆ is R';

R₁₄ and R₁₅ are both -R'; and

A is hydrogen.

11. The compound according to claim 10, wherein:

10 R₁₄ and R₁₅ are both -R' and R' is (C1-C12)-aliphatic-.

12. The compound according to claim 2, wherein:

R₁₈ and R₁₈' are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system;

wherein the R₁₈ and R₁₈' atoms bound to the carbon atom are independently O or N;

wherein said ring optionally contains up to 1 additional heteroatom selected from N, NH, O, S, SO, and SO₂;

wherein any substitutable atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J;

wherein said ring is optionally fused to a second ring selected from (C6-C10)aryl, (C5-C10)heteroaryl, 15 (C3-C10)cycloalkyl, and a (C3-C10)heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J;

U is a bond;

R₁₆ is R';


R_{14} and R_{15} are both $-R'$; and
A is hydrogen.

13. The compound according to claim 12;
wherein the R_{18} and R_{18}' atoms bound to the carbon
atom are O;
wherein said ring optionally contains up to 1
additional oxygen atom.


5 14. The compound according to any one of claims 1-
13, wherein R_{14} and R_{15} are both $-R'$ and R' is
(C1-C6)-aliphatic-.

10 15. The compound according to claim 14, wherein R_{14}
and R_{15} are both methyl.

16. The compound according to any one of claims 1-
15, wherein the




radical is:




wherein:

n is 0, 1, or 2;
 Z and Z' are independently C(H), N, NH, O, or S;
 R_9 , R_9' , R_{11} , and R_{11}' are as defined in claim 1; and
the spirocyclic ring containing Z and Z' is
optionally substituted with up to 3 J substituents,
wherein J is as defined in claim 1.

17. The compound according to claim 16, wherein:



radical is:



wherein:


R_{11} and $R_{11'}$ are both H;

n is 0, 1, or 2;


R_9 and $R_{9'}$ are as defined in claim 1; and

the spirocyclic ring containing Z and Z' is optionally substituted with up to 3 J substituents, wherein J is as defined in claim 1.

18. The compound according to claim 17, wherein the




radical is:




wherein:

n is 0 or 1.

19. The compound according to any one of claims 1-15, wherein the



radical is:



wherein:

R_9 , $R_{9'}$, $R_{10'}$, R_{11} , and $R_{11'}$ are as defined in claim 1;

and

R' is:

(C6-C10)-aryl-,

(C6-C10)-aryl-(C1-C12)aliphatic-,

(C3-C10)-heterocyclyl-,


(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,

(C5-C10)-heteroaryl-, or


(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 5 atoms in R' are optionally and independently substituted with J.

20. The compound according to claim 19, wherein the




radical is:




wherein the R' ring is optionally substituted with up to 5 substituents independently selected from J.

21. The compound according to any one of claims 1-15, wherein the



radical is:



;

wherein:

R_9 , $R_{9'}$, $R_{10'}$, R_{11} , and $R_{11'}$ are as defined in claim 1; and

R' is selected from:


(C6-C10)-aryl-(C1-C12)aliphatic-,

(C3-C10)-heterocyclyl-(C1-C12)aliphatic-, and


(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 5 atoms in R' are optionally and independently substituted with J.


22. The compound according to claim 21, wherein the



radical is:




or



;

23. The compound according to any one of claims 1-15, wherein in the



radical

R_9 , R_{10} , $R_{10'}$, R_{11} , and $R_{11'}$ are as defined in claim 1;

and

R_9 is:


(C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-;


wherein up to three aliphatic carbon atoms in R₉' may be replaced by O, N, NH, S, SO, or SO₂; and

wherein R₉' is independently and optionally substituted with up to 3 substituents independently selected from J.


24. The compound according to claim 23, wherein the



radical is:



25. The compound according to any one of claims 1-15, wherein in the



radical

R₉, R₉', R₁₀, R₁₀', and R₁₁ are H; and

R₁₁' is:

(C1-C12)-aliphatic-,

5 (C3-C10)-cycloalkyl- or -cycloalkenyl-,


(C6-C10)-aryl-,

wherein any ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;


10 wherein up to 3 aliphatic carbon atoms in R₁₁' may be replaced by a heteroatom selected from O, NH, S, SO, or SO₂ in a chemically stable arrangement;

wherein R_{11} , is independently and optionally substituted with up to 3 substituents independently selected from J.

26. The compound according to claim 25, wherein the formula I, the



27. The compound according to any one of claims 1-15, wherein in the



R_9 , R_{10} , R_{11} , and R_{11} , are H; and

R_9 , and R_{10} , are:


(C1-C12)-aliphatic-,


(C3-C10)-cycloalkyl- or -cycloalkenyl-,

wherein up to 3 aliphatic carbon atoms in R_9 , and R_{10} , may be replaced by a heteroatom selected from O, NH, S, SO, or SO₂ in a chemically stable arrangement; and



wherein R_9 , and R_{10} , are independently and optionally substituted with up to 3 substituents independently selected from J.

28. The compound according to claim 27, wherein the





29. The compound according to any one of claims 1-15, wherein the



wherein;



ring A is a 5- to 6-membered aromatic or a 3- to 7-membered non-aromatic ring system having up to 3 heteroatoms independently selected from N, NH, O, SO, or SO₂;

wherein said ring A is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;



wherein any ring has up to 3 substituents selected independently from J; and

R₉, R₉', R₁₀', and R₁₁' are as defined in claim 1.



30. The compound according to claim 29, wherein the





31. The compound according to claim 30, wherein the



32. The compound according to claim 31, wherein the



33. The compound according to any one of claims 1-15, wherein the



wherein:

ring B forms a 3- to a 20-membered carbocyclic or heterocyclic ring system;

wherein each ring B is either aromatic or nonaromatic;



wherein each heteroatom in the heterocyclic ring system is N, NH, O, SO, or SO₂;

wherein ring B is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;


wherein each ring has up to 3 substituents selected independently from J; and

R₉' and R₁₁' are as defined in claim 1.

34. The compound according to claim 33, wherein the




35. The compound according to any one of claims 1-34, wherein W is:




wherein in the W, the NR₆R₆ is selected from -NH-(C1-C6 aliphatic), -NH-(C3-C6 cycloalkyl), -NH-CH(CH₃)-aryl, or -NH-CH(CH₃)-heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with up to 3 halogens.


36. The compound according to claim 35, wherein in the W, the NR₆R₆ is:




37. The compound according to claim 36, wherein in the W, the NR_6R_6 is:




38. The compound according to claim 37, wherein in the W, the NR_6R_6 is:




39. The compound according to claim 38, wherein in the W, the NR_6R_6 is:



40. The compound according to any one of claims 1-39, wherein R_5 is hydrogen and R_5 is:




41. The compound according to claim 40, wherein R₅ is hydrogen and R₅ is:




42. The compound according to any one of claims 1-41, wherein R₂, R₄, R₇, and R₁₂' are each independently H, methyl, ethyl, or propyl.

43. The compound according to claim 42, wherein R₂, R₄, R₇, and R₁₂, are each H.


44. The compound according to any one of claims 1-43, wherein R_3 is:




45. The compound according to claim 44, wherein R₃ is:




46. The compound according to claim 45, wherein R^3 is:



47. The compound according to any one of claims 1-46, wherein R^1 is:



48. The compound according to claim 47, wherein R_1 is:



49. The compound according to claim 48, wherein R_1 is cyclohexyl.

50. A pharmaceutical composition comprising a compound according to any one of claims 1-49 or a pharmaceutically acceptable salt thereof in an amount effective to inhibit a serine protease; and a acceptable carrier, adjuvant or vehicle.

51. The composition according to claim 50, wherein said composition is formulated for administration to a patient.

52. The composition according to claim 51, wherein said composition comprises an additional agent selected from an immunomodulatory agent; an antiviral agent; a second inhibitor of HCV protease; an inhibitor of another target in the HCV life cycle; and a cytochrome P-450 inhibitor; or combinations thereof.

53. The composition according to claim 50, wherein said immunomodulatory agent is α -, β -, or γ -interferon or thymosin; said antiviral agent is ribavirin, amantadine, or telbivudine; or said inhibitor of another target in the HCV life cycle is an inhibitor of HCV helicase, polymerase, or metalloprotease.

54. The composition according to claim 52, wherein said cytochrome P-450 inhibitor is ritonavir.

55. A method of inhibiting the activity of a serine protease comprising the step of contacting said serine protease with a compound according to any one of claims 1-49.

56. The method according to claim 55, wherein said serine protease is an HCV NS3 protease.

57. A method of treating an HCV infection in a patient comprising the step of administering to said patient a composition according to claim 51.

58. The method according to claim 57, comprising the additional step of administering to said patient an additional agent selected from an immunomodulatory agent; an antiviral agent; a second inhibitor of HCV protease; an inhibitor of another target in the HCV life cycle; or combinations thereof; wherein said additional agent is administered to said patient as part of said composition according to claim 51 or as a separate dosage form.

59. The method according to claim 58, wherein said immunomodulatory agent is α -, β -, or γ -interferon or thymosin; said antiviral agent is ribavirin or amantadine; or said inhibitor of another target in the HCV life cycle is an inhibitor of HCV helicase, polymerase, or metalloprotease.


60. A method of eliminating or reducing HCV contamination of a biological sample or medical or laboratory equipment, comprising the step of contacting said biological sample or medical or laboratory equipment with a composition according to claim 50.

61. The method according to claim 60, wherein said sample or equipment is selected from blood, other body fluids, biological tissue, a surgical instrument, a surgical garment, a laboratory instrument, a laboratory garment, a blood or other body fluid collection apparatus; a blood or other body fluid storage material.

62. The method according to claim 61, wherein said body fluid is blood.

63. A process for preparing a compound of formula I, as defined in any one of claims 1-49, comprising the


step of: reacting a compound of formula VII in the presence of a compound of formula VIII to provide a compound of formula IX:



VII



VIII



IX

wherein:

R₂₁ is an amine protecting group, a P3- residue of an HCV protease inhibitor described herein, or a P4-P3- residue of an HCV protease inhibitor as described herein, and wherein the P3 and the P4-P3 residues are optionally protected with an amino-terminal capping group;

R₂₀ is a carboxy protecting group or a P1 residue of an HCV protease inhibitor described herein, wherein the P1 residue is optionally protected with a carboxy terminal protecting group or with W; R' is as defined in claim 1; and X is an appropriate leaving group.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/011011

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D403/12 C07K5/10 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/006490 A1 (VERTEX PHARMACEUTICALS INCORPORATED, USA) 23 January 2003 (2003-01-23) compound 16 in Table 1, claims 1,22-24,36-39,45; table 1 -----	1,2,14, 15, 33-41, 44-53, 60-62
A	WO 98/17679 A (DEININGER DAVID D ; MURCKO MARK A (US); VERTEX PHARMA (US); FARMER LUC) 30 April 1998 (1998-04-30) compound 153 in Table 1 page 1; claim 1; table 1 ----- -/--	1-62

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

9 September 2004

Date of mailing of the international search report

30/09/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Guspanova, J

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US2004/011011

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	<p>WO 03/087092 A2 (VERTEX PHARMACEUTICALS, INC., USA) 23 October 2003 (2003-10-23)</p> <p>the whole document claims 1,12,26,30-37; table 5; compounds 25,25A,33A,41A,45A,55A,58A,59A,61A,62A,63-68</p> <p>-----</p>	<p>1,2,14, 15, 19-21, 23,24, 29-41, 44-53, 60-62</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2004/011011

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 55-59 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/011011

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03006490	A1	23-01-2003	CA 2449504 A1	23-01-2003
			EP 1404704 A1	07-04-2004
			US 2003119752 A1	26-06-2003
WO 9817679	A	30-04-1998	AP 1019 A	16-10-2001
			AT 212037 T	15-02-2002
			AU 719984 B2	18-05-2000
			AU 5147798 A	15-05-1998
			BG 103392 A	31-01-2000
			BR 9712544 A	19-10-1999
			CA 2268391 A1	30-04-1998
			CN 1238780 A , B	15-12-1999
			CZ 9901340 A3	11-08-1999
			DE 69709671 D1	21-02-2002
			DE 69709671 T2	22-08-2002
			DK 932617 T3	22-04-2002
			EA 1915 B1	22-10-2001
			EE 9900161 A	15-12-1999
			EP 1136498 A1	26-09-2001
			EP 0932617 A1	04-08-1999
			ES 2169880 T3	16-07-2002
			HK 1023779 A1	27-09-2002
			HU 0000152 A2	28-07-2000
			ID 21649 A	08-07-1999
			IN 183120 A1	11-09-1999
			JP 2001502694 T	27-02-2001
			KR 2000049263 A	25-07-2000
			NO 991832 A	17-06-1999
			NZ 335276 A	29-09-2000
			PL 332872 A1	25-10-1999
			PT 932617 T	28-06-2002
			SI 932617 T1	30-06-2002
			SK 51099 A3	10-04-2000
			TR 9901602 T2	21-10-1999
			TW 530065 B	01-05-2003
			WO 9817679 A1	30-04-1998
			US 6265380 B1	24-07-2001
			US 2002032175 A1	14-03-2002
			ZA 9709327 A	11-05-1998
WO 03087092	A2	23-10-2003	US 2004018986 A1	29-01-2004